Original source text
Corning chairman and CEO Wendell Weeks discusses the company's newly announced partnership with Amazon to expand fiber-optic production for data centers on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #amazon #ai #artificialintelligence #technology #business #economy #datacenter #infrastructure #fiber #fiberoptic #cloud #innovation #manufacturing #growth #investment #markets #amazonwebservices #leadership Live financial news intelligence
Track market-moving stories before they get noisy
Real-time pulse of financial headlines curated from 5 premium feeds.
Latest market signal
English
Commodities
GOLD
233
SILVER
130
OIL
61
PLATINUM
5
PALLADIUM
2
COPPER
1
- FMP Stock News 33s ago
- FMP Forex News 33s ago
- CoinGecko News 33s ago
- FIO Stock News 4m ago
- Patria Stock News 4m ago
- Editorial rewrite running now
- Asset sync 44m ago
Latest coverage
Market News Feed
Scan headlines quickly, then expand any story for source context.
| Details | Date | Content | Source |
|---|---|---|---|
|
Saved
2026-06-13 18:32
1mo ago
Published
2026-06-13 14:00
1mo ago
|
EXPANSION: Corning and Amazon deepen AI infrastructure partnership | FMP Stock News | |
|
|
|||
|
Saved
2026-06-13 18:32
1mo ago
Published
2026-06-13 14:13
1mo ago
|
Amazon voiced concerns about Anthropic AI models before US government's crackdown, source says | FMP Stock News | |
|
Original source text
Amazon CEO Andy Jassy speaks during an Amazon Devices launch event in New York City, U.S., February 26, 2025. REUTERS/Brendan McDermid Purchase Licensing Rights, opens new tabJune 13 (Reuters) - Amazon (AMZN.O), opens new tab CEO Andy Jassy was among tech leaders who raised concerns to senior Trump administration officials this week about security risks in Anthropic’s most advanced AI models, a person familiar with the matter told Reuters. Amazon did not immediately respond to a request for comment. The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here. Citing national security concerns, the Trump administration on Friday directed Anthropic to block any foreign nationals, whether inside or outside the U.S., from using its latest models, Fable 5 and Mythos 5. In response, Anthropic said it would disable access to the models globally. In a blog post, Anthropic said on Friday that the U.S. government believes there is a method of bypassing, or "jailbreaking," a safeguard that would prevent Fable 5 from being used in identifying software vulnerabilities, the company said. The U.S. government restrictions came in the form of an export control, Anthropic said in its blog post. The U.S. Commerce Department's Bureau of Industry and Security, which oversees export controls, did not immediately respond to a request for comment. Some experts who favor export controls on advanced AI models found the Trump administration's action puzzling because it affects allied nations as well as adversaries. “This was not well thought-out," said Jimmy Goodrich, a senior fellow at the University of California's Institute for Global Conflict and Cooperation. "It even bans Canadians and Brits employed at Anthropic from doing research and development.” Reporting by Abu Sultan in Bengaluru, and Stephen Nellis and Greg Bensinger in San Francisco; Editing by Sergio Non and Matthew Lewis Our Standards: The Thomson Reuters Trust Principles., opens new tab |
|||
|
Saved
2026-06-13 18:27
1mo ago
Published
2026-06-13 12:06
1mo ago
|
Intel Just Got a Rare Double Upgrade From Bank of America. Here's the AI Shift Behind the Call. | FMP Stock News | |
|
Original source text
Most analyst rating changes move a single notch. So when one of the more closely followed semiconductor analysts skips the middle rating and jumps two rungs at once, it's worth a closer look -- not necessarily as a reason to buy, but as a window into how the thinking around artificial intelligence (AI) spending may be changing.That's what happened on June 11, when Bank of America's Vivek Arya double-upgraded Intel (INTC +6.49%) to buy from underperform, lifting his price target to $135 from $96. Banks tend to reserve a move like that for moments when the thesis they had been betting against breaks. And it came after Intel had already more than tripled in 2026 -- less a call on a forgotten stock than a bet that the turnaround has further to run. Intel shares rose about 6% in the following session, closing near $125 as of this writing. The more useful question isn't whether the target is right. It's what the upgrade says about the next phase of the AI trade. Image source: Getty Images. The case for the CPU For most of the AI boom, the story has been about graphics processing units (GPUs) -- the chips that train large models. Central processors, Intel's historical stronghold, were an afterthought. The upgrade rests on the idea that this is starting to change. The argument goes like this: as companies build "agentic" systems in which software agents carry out tasks independently, incremental work shifts to the central processors to coordinate those agents. If that shift plays out, the market for server processors will get much bigger. Indeed, Bank of America now pegs the market at more than $170 billion by 2030, up from a prior estimate of around $125 billion, and sees Intel capturing roughly a quarter of it. Intel's own recent numbers lend the idea some support. In the first quarter of 2026 (the period ended March 28, 2026), the company's data center and AI revenue rose 22% year over year to about $5.1 billion -- easily the fastest-growing of its three main segments, well ahead of the 1% growth in its client computing group, which sells PC chips. And management is describing the central processor in much the same terms. "In recent months, we have seen clear signs that the CPU is reasserting itself as the indispensable foundation of the AI era," said Intel CEO Lip-Bu Tan in the company's first-quarter earnings call. A risky foundry business The second part of the upgrade is about manufacturing. Intel is trying to become a more formidable contract chipmaker, producing chips for others the way Taiwan Semiconductor does -- a business it calls its foundry. This, however, is the higher-risk, higher-reward part of the story. Bank of America pointed to a pipeline of potential outside customers, including reported work on Apple's chips and MediaTek's processors. If even a few of those deals scale, the foundry could grow from a rounding error into a real second engine. But Intel isn't there yet. Intel's external foundry revenue -- the part that comes from outside customers rather than its own products -- was just $174 million in the first quarter. And the foundry segment as a whole is still losing billions of dollars a year as Intel spends heavily to build out advanced manufacturing. And closing the gap with Taiwan Semiconductor is something Intel has tried and stumbled at before. Today's Change ( 6.49 %) $ 7.59 Current Price $ 124.55 Then there's the price. Intel trades at well over 100 times its expected earnings for the next year. A valuation like this leaves little room for error, assuming both the agentic-processor shift and the foundry turnaround unfold with very few blips along the way. So, what do I make of all this? The rotation Bank of America is describing looks real and underappreciated -- the idea that AI's next phase pulls spending back toward the processors and manufacturing capacity Intel is built around. But a compelling thesis and an attractive entry price are different things. After more than tripling this year, the stock has arguably already priced in much of that optimism, and the bar it now has to clear is far higher than it was a few months ago. I'd want to see Intel's foundry business make more meaningful progress on its pipeline before treating the stock as a buy here. Sure, the shift may be coming. But the stock apparently isn't waiting around for proof. |
|||
|
Saved
2026-06-13 18:22
1mo ago
Published
2026-06-13 13:15
1mo ago
|
Costco vs. Walmart vs. Amazon: Which Stock Is the Smartest Buy in 2026? | FMP Stock News | |
|
Original source text
Costco Wholesale (COST +0.67%), Walmart (WMT +0.44%), and Amazon (AMZN 1.24%) have all carved out their own niche in serving retail shoppers. Walmart is known for low prices, Costco sells bulk items, and Amazon sells and ships pretty much anything you need.As investments, they are also all unique in how they can fit into a portfolio. Finding the winner between the three comes down to holding periods and investing goals. Image source: Getty Images. The membership model that keeps making money Walking through a Costco is often described as being on a treasure hunt, with some members even sharing their shopping trips on social media. With its bulk deals and private-label Kirkland Signature brand, Costco has built a loyal following that helps it boast an impressive membership renewal rate. As of its fiscal Q3 2026, Costco's membership renewal rate in the U.S. and Canada was 92.2%, while its worldwide membership renewal rate was 89.7%. Mostly known for its warehouse shopping experience, Costco is also seeing positive results from connecting more with its customers online. In the third quarter, e-commerce site and app traffic rose 37%, while digitally enabled comparable sales increased 21.5%. While the quarter was strong and the company generally met or slightly beat expectations, the report wasn't enough to impress investors, and the stock price has recently dipped. Costco is richly valued, with a forward price-to-earnings ratio of 43.1, so expectations are high. Still, over the last five years, Costco has done well by its shareholders, with the stock climbing over 150%. It's also a dividend payer, and while that yield is on the smaller side at 0.6%, Costco is also known for paying out a special dividend from time to time. In 2024, the one-time special dividend payout was $15 per share. Today's Change ( 0.67 %) $ 6.58 Current Price $ 982.27 Constant dividends with a side of tech Walmart is the only Dividend King on the list, earning that title by increasing its dividend payout for 50 or more consecutive years. That shows stability in the company's business model, because no matter what is going on in the economy, it has consistently rewarded its shareholders with dividend increases for the past 53 years. That comes from having a reliable business model. Unlike some other Dividend Kings, however, Walmart is also known for providing stock price appreciation, particularly over the last five years, with shares also up over 150%, like Costco. That growth can continue over the long term as it infuses more technology into its business, such as its artificial intelligence (AI) shopping agent, Sparky. It also has growing revenue from its Walmart+ membership and a budding advertising division. Today's Change ( 0.44 %) $ 0.54 Current Price $ 121.03 Follow the AI leader Amazon has a retail presence like Walmart and Costco, and it also has a grocery component through its ownership of Whole Foods. But there's an even bigger opportunity outside of the retail sector for Amazon. Much as in the chip sector for AI, where most roads lead to Nvidia, that's increasingly becoming true with Amazon's cloud business. In its 2026 first-quarter earnings report, Amazon announced new Amazon Web Service (AWS) agreements with Anthropic, Meta Platforms, Nvidia, OpenAI, and Uber Technologies. In that report, Amazon also announced that AWS revenue increased 28% to $37.6 billion, which was its fastest revenue growth in 15 quarters. For Amazon, the only catch is that it is judged more as a tech company than a retailer. Tech stocks are usually the first stocks investors rotate out of during periods of heightened economic uncertainty, as they are seen as risky. Today's Change ( -1.24 %) $ -2.98 Current Price $ 238.53 The winning stock Walmart, Costco, and Amazon are well-run companies, and each could be worth holding in a portfolio. But with the idea that you'd be buying a stock in 2026 to hold for years or decades for stock price appreciation, Amazon could offer the most potential thanks to its AI opportunities. It's making heavy investments to win the AI race against other big tech companies, but as those capital expenditures start showing up as revenue and margins improve, that can help the stock price break out. For long-term investors seeking reliable income, however, Walmart is worth considering. The dividend yield is on the lower side at 0.8%, but that indicates a sustainable yield. Plus, while Amazon could offer more long-term stock price appreciation because of its cloud services and involvement in AI, Walmart's dividend payout can help increase its total return potential. |
|||
|
Saved
2026-06-13 18:18
1mo ago
Published
2026-06-13 10:58
1mo ago
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zillow Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - Z, ZG | FMP Stock News | |
|
Original source text
New York, New York--(Newsfile Corp. - June 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301355 Source: The Rosen Law Firm PA Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs. Contact Us |
|||
|
Saved
2026-06-13 18:17
1mo ago
Published
2026-06-13 12:00
1mo ago
|
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting | FMP Stock News | |
|
Original source text
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing therapies and a novel treatment option for patients who become resistant to type I JAK2 inhibitors. Lilly recently added this program to its pipeline following the completion of the acquisition of Ajax Therapeutics, Inc.These data will be highlighted in an oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting taking place in Stockholm, Sweden (Abstract number: S218) and featured in the meeting's press program. "Patients with myelofibrosis who have been previously treated with an existing type I JAK2 inhibitor face very limited treatment options, highlighting an urgent need for new therapies," said John Mascarenhas, MD, professor of medicine, Icahn School of Medicine at Mount Sinai and principal investigator of the AJX-101 study. "These early clinical findings suggest that selective targeting of the type II conformation of JAK2 may provide a differentiated approach. With an encouraging safety profile, meaningful spleen size reduction, symptom improvement, and decrease in underlying mutant disease burden, these data, while early, point to the potential to meaningfully impact treatment options for people with certain myeloproliferative neoplasms." AJX-101 is the first clinical trial to evaluate a type II selective JAK2 inhibitor in patients with myelofibrosis. The trial enrolled 23 patients across five dose levels (25, 50, 75, 100, and 125 mg once daily) in its dose escalation phase. Patients had received a median of two prior therapies, and all had previously received a type I JAK2 inhibitor. The trial enrolled patients across all major myelofibrosis subtypes and driver mutations. AJ1-11095 demonstrated responses across the standard efficacy endpoints of spleen volume reduction and symptom improvement.1 The SVR35 rate, a reduction in spleen volume of at least 35%, was observed as best response in 70% of patients. The TSS50 rate, indicating at least a 50% improvement in symptom burden, was also seen in 70% of patients at week 12. In addition, reductions in driver mutation variant allele frequency (VAF) were observed in 21 out of 23 patients. Among the 17 patients who reached week 24 of treatment, 59% saw a reduction of 20% or greater and 35% saw a reduction of 50% or greater, including JAK2, MPL, and CALR type 1 and type 2 mutations. VAF reductions are uncommonly observed with existing type I JAK2 inhibitors.2 The overall safety profile for the medicine was generally manageable. No dose-limiting toxicities were observed, and most patients enrolled in the dose escalation phase remain on study (78%).3 The most common treatment-emergent adverse events across all dose levels included anemia, dysgeusia, decreased platelet count, and increased alanine aminotransferase. "The depth of response seen across spleen, symptoms, and VAF from these early phase results is in excess of what has been seen historically in this disease setting," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "These data provide clear proof of concept for what this selective type II JAK2 inhibitor could mean for patients with myelofibrosis and shed light on the conviction we brought to the acquisition of Ajax. With this program now officially part of Lilly's pipeline, we are committed to rapidly advancing it through clinical development and further exploring its potential to meaningfully improve outcomes for people with myeloproliferative neoplasms across a range of disease settings." AJ1-11095 is currently being evaluated in an expansion cohort in second-line myelofibrosis, with plans to investigate in patients with high-risk polycythemia vera and those with myelofibrosis who have not yet received a JAK2 inhibitor. Details on the AJX-101 trial can be found by visiting clinicaltrials.gov. About AJ1-11095 AJ1-11095 is an investigational, oral, first-in-class type II JAK2 inhibitor. AJ1-11095 is designed to bind JAK2 in its inactive conformation — an approach intended to more completely suppress the aberrant signaling that drives myelofibrosis, in contrast to currently approved JAK2 inhibitors that bind JAK2 in its active state. AJ1-11095 demonstrated superior activity compared to ruxolitinib in preclinical models of myelofibrosis. AJ1-11095 is currently being studied in AJX-101, a global, open-label, multicenter, Phase 1 study in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have previously been treated with a type I JAK2 inhibitor, NCT06343805. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY © Lilly USA, LLC 2026. ALL RIGHTS RESERVED. Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about AJ1-11095 as a potential treatment for adults with myelofibrosis and other myeloproliferative neoplasms, and the timeline for future studies, regulatory submissions, presentations, and other milestones relating to AJ1-11095 and the AJX-101 clinical program, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned or that future study results will be consistent with study results to date. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. _________________________________ 1 May 28, 2026 data cutoff 2 Meyer SC et al Cancer Cell 2015: 28:P15-28 3 May 12, 2026 data cutoff View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-present-initial-clinical-data-for-first-in-class-type-ii-jak2-inhibitor-in-patients-with-previously-treated-myelofibrosis-at-the-2026-eha-annual-meeting-302799309.html SOURCE Eli Lilly and Company |
|||
|
Saved
2026-06-13 18:13
1mo ago
Published
2026-06-13 13:00
1mo ago
|
Joe Sticco on Bull Case for Bitcoin's Recovery & MSTR Influence Over Crypto Move | FMP Stock News | |
|
Original source text
Bitcoin is following its traditional four-year cycle, says Joe Sticco, who sees a strong recovery in the cryptocurrency toward the back half of the year. Congress approving the Clarity Act will be the biggest step for Bitcoin's momentum, says Joe, pointing to what will likely lead to a large inflow in institutional buyers. |
|||
|
Saved
2026-06-13 18:11
1mo ago
Published
2026-06-13 12:15
1mo ago
|
Plug Power Is Undergoing a Massive Transformation: Here Are 3 Things Investors Need to Know | FMP Stock News | |
|
Original source text
For over a quarter of a century, Plug Power (PLUG 2.47%) has been building out a hydrogen infrastructure ecosystem, but its efforts have borne little fruit. Since going public, Plug Power has never turned an annual profit.The company is looking to buck its 25-year trend and lean into its most promising businesses while cutting those that have been dragging it down, and the transformation could make it a worthwhile investment. However, before you buy the stock, here are three things to know about Plug Power's makeover. Today's Change ( -2.47 %) $ -0.07 Current Price $ 2.76 1. Its Project Quantum Leap aims to improve efficiency Plug Power has spent nearly three decades developing a vertically integrated, end-to-end hydrogen ecosystem. To achieve this, the company has diversified into a range of products and services, including hydrogen-powered forklifts, electrolyzers for hydrogen generation, hydrogen liquefiers, trailers, and tankers. The move gives Plug Power a wide range of offerings, but it has been extremely expensive. Last year, the company's net loss was $1.6 billion, and since its inception, Plug Power has an accumulated deficit of about $8.2 billion. In an effort to turn things around, management is embarking on Project Quantum Leap, which aims to make operations leaner while leaning into its higher-margin offerings. PLUG Revenue (TTM) data by YCharts The company's first-quarter earnings results showed some progress in management's efforts. During the period, its gross margin of negative 13% was a drastic improvement from a year ago, when it was negative 55%. Meanwhile, its adjusted earnings per share (EPS) improved from negative $0.17 last year to negative $0.08 in the most recent quarter. Management believes it can achieve positive earnings before interest, taxes, depreciation, and amortization (EBITDA) in the fourth quarter of this year. 2. Electrolyzer equipment is showing promising growth As part of Plug Power's transformation, the company is leaning into its most promising offerings, with electrolyzers a strong driver of growth. These devices use energy to split water into hydrogen and oxygen gases, with the hydrogen then captured and stored for later use as fuel. In the first quarter, Plug's electrolyzer revenue surged 343% year over year to $40.8 million. This comes after the company already had a very strong 2025, where it generated $52.3 million in electrolyzer revenue, driven by strong demand in Europe. What makes electrolyzers appealing for Plug Power is that they provide operational leverage and offer higher margins. Another driver of growth here is regulatory mandates in Europe, specifically the European Union's RED III directive, which is designed to accelerate the region's adoption of clean energy. Management noted that meeting these mandates could require 4 to 6 gigawatts of electrolyzer capacity by 2030. Image source: The Motley Fool. 3. It has expanded in-house fuel production and signed a sourcing agreement In addition to equipment sales, Plug Power is reducing its reliance on expensive third-party hydrogen and producing more of this fuel in-house. The company has hydrogen production plants in Tennessee, Georgia, and Louisiana, with a combined production capacity of roughly 40 tons of liquid hydrogen per day. Scaling these hydrogen plants is another major component of Project Quantum Leap and a big reason the company's margins improved so much in the first quarter. By producing fuel in-house, Plug Power has secured its hydrogen fuel supply chain, a key part of its efforts to build an end-to-end, integrated business model. In addition to in-house production, Plug Power has signed a deal with a major industrial gas company. Management noted that this deal resulted in a "substantial reduction in the cost per kilogram" of purchased fuel. Because its facilities are in the southeast, this third-party sourcing enables Plug Power to deliver fuel to customers in the western and northeastern United States without incurring expensive transportation costs. Plug Power is a stock to watch Plug Power is making a serious effort to improve its business outlook by pairing its high-margin electrolyzer equipment pipeline with an optimized, vertically integrated domestic fuel network. Investors buying today are betting that Plug Power can transform from a speculative, cash-burning company to a profitable company operating across the hydrogen ecosystem. |
|||
|
Saved
2026-06-13 18:08
1mo ago
Published
2026-06-13 11:00
1mo ago
|
PicS N.V. (PICS) Class Action Lawsuit: Investors Face August 4, 2026, Deadline | FMP Stock News | |
|
Original source text
Did you buy PICS Class A common stock on or around January 30, 2026?Affected PICS Investor Summary Who: PicS N.V. (NASDAQ: PICS)What: Securities fraud class action lawsuit filedClass Period: pursuant and/or traceable to PicS's initial public offering (IPO) on or about January 30, 2026Deadline to Seek Lead Plaintiff Status: August 4, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's credit models and user data.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against PicS N.V. (PicS) (NASDAQ: PICS) on behalf of those who purchased or acquired PicS Class A common stock pursuant and/or traceable to PicS's January 30, 2026 IPO. The lawsuit is filed in the United States District Court for the Southern District of New York and is captioned FirstFire Global Opportunities Fund, LLC v. PicS N.V., Case No. 1:26-cv-04793 (S.D.N.Y). Investors have until August 4, 2026, to file for lead plaintiff status. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired PicS Class A common stock and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at: Phone: (484) 270-1453 Email: [email protected] Website: https://www.ktmc.com/pics-pics-nv-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=pics&mktm=PR There is no cost or obligation to speak with an attorney. PICS N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY: The complaint alleges that PicS's IPO documents contained materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) PicS had conducted an evaluation of its credit evaluation procedures in December 2025 and determined that such procedures were deficient and in need of enhancement; (2) as a result of the new procedures PicS had implemented in December 2025, PicS had reclassified approximately R$590 million of exposures previously classified as Stage 2 to Stage 3, leading to an incremental Expected Credit Loss (ECL) charge of R$88 million in the three months ended December 31, 2025; (3) PicS had experienced a heightened, but unreported, Stage 3 formation rate of more than 7% in the fourth quarter of 2025 that deviated substantially from the historical results and trends provided in the IPO documents; (4) the IPO documents had materially overstated the quality and ability of PicS's credit models and user data to inform the company's underwriting practices and to allow PicS to timely and effectively monitor, assess, and identify adverse credit events, credit risks, and credit deterioration across its portfolio; (5) PicS suffered from degradations in customer credit quality and heightened risks of default and loan impairment as a result of its entrance into materially riskier business lines leading up to the IPO, resulting in undisclosed adverse financial and operational trends such as heightened incidents of default, which predated the IPO and were internally projected by PicS to continue to worsen following the IPO; and (6) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. At the time of filing of the complaint, PicS's stock price had fallen to a low of less than $9 per share, representing a more than 50% decline from the $19 per share IPO price. WHAT PICS INVESTORS CAN DO NOW: File to be lead plaintiff by August 4, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action.THE LEAD PLAINTIFF PROCESS FOR PICS N.V. INVESTORS: PicS investors may, no later than August 4, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages PicS investors to contact the firm for more information. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. The complaint in this matter was not filed by KTMC. CONTACT: Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View original content to download multimedia:https://www.prnewswire.com/news-releases/pics-nv-pics-class-action-lawsuit-investors-face-august-4-2026-deadline-302799265.html SOURCE Kessler Topaz Meltzer & Check, LLP |
|||
|
Saved
2026-06-13 18:03
1mo ago
Published
2026-06-13 11:15
1mo ago
|
Do Higher Oil Prices Mean Rivian Stock Will Finally Mount a Rebound? | FMP Stock News | |
|
Original source text
The sales of used electric vehicles took off as oil prices rose earlier in the year. That's an early sign that consumers may be looking for a way to avoid having to deal with rising gasoline costs. And it makes the story behind Rivian (RIVN +7.63%) more compelling. However, execution will still determine Rivian's success. Here's what you need to know before you buy the stock.Rivian has achieved great things Rivian is attempting to build a sustainably profitable business selling electric vehicles, with a focus on trucks. So far, it has proven it can make award-winning vehicles, produce them at scale, and sell them for more than it costs to build them (it had a gross profit in 2025). As a business, Rivian has made huge strides. Image source: Getty Images. However, it still hasn't generated positive earnings. The goal is to ramp up production so it can spread its costs over more vehicles. Management hopes that this will allow it to become sustainably profitable. That is, basically, what allowed Tesla (TSLA +1.65%) to get into, and stay in, the black. High gasoline prices are a positive development because they make electric vehicles more attractive. However, high gas prices alone won't be enough to sustain a rebound in Rivian's stock. The big story is Rivian's lower-cost R2 model The next big step in Rivian's story is the launch of a mass-market version of its high-end truck. The company is now rolling out the lower-cost truck, known as the R2, to the market. The big question is how well received it will be by consumers. Today's Change ( 7.63 %) $ 1.19 Current Price $ 16.73 High gas prices help, but they probably won't be the main factor in consumer buying decisions. After all, there are plenty of other EVs that a person can buy. Curb appeal will likely be the biggest factor, though cost will clearly play a role, as well. If the R2 is desirable and the price is low enough to attract mass-market buyers, it will be a success. And that, in turn, could lead to a sustained recovery in Rivian's stock price as it inches closer to becoming a sustainably profitable business. If the R2 is too expensive or the vehicle just doesn't resonate with car buyers, Rivian will have a hard time ahead. Rivian: Execution is the vital factor Rivian's R2 looks a lot like its popular R1 trucks. There's no reason to believe it won't be popular, too. However, this is a make-or-break moment for the company. Rivian's future is very uncertain if the R2 isn't popular enough. The stock is only appropriate for more aggressive growth investors, and you'll want to pay close attention to how well the R2 sells in the quarters ahead, high gas prices or not. |
|||
|
Saved
2026-06-13 17:53
1mo ago
Published
2026-06-13 12:05
1mo ago
|
Kratos Defense & Security Solutions, Inc: Why I Am Buying The Dip | FMP Stock News | |
|
Original source text
Kratos Defense & Security Solutions (KTOS) is positioned to capture defense spending that legacy primes cannot match on cost or agility. KTOS benefits from three structural tailwinds: US drone procurement priorities, attritable warfare doctrine, and hypersonic systems moving to production. Q1 2026 results show 22.6% YoY revenue growth, 1.6x book-to-bill, record $2.01B backlog, and a $14B+ opportunity pipeline. |
|||
|
Saved
2026-06-13 17:45
1mo ago
Published
2026-06-13 10:30
1mo ago
|
Build Your Wealth With Happy Dividends | FMP Stock News | |
|
Original source text
126.55K FollowersAnalyst’s Disclosure: I/we have a beneficial long position in the shares of EPR, VICI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Beyond Saving, Philip Mause, and Hidden Opportunities, all are supporting contributors for High Dividend Opportunities. Any recommendation posted in this article is not indefinite. We closely monitor all of our positions. We issue Buy and Sell alerts on our recommendations, which are exclusive to our members. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. |
|||
|
Saved
2026-06-13 17:43
1mo ago
Published
2026-06-13 11:31
1mo ago
|
IMF: Uncorrelated Managed Futures Strategy From Invesco | FMP Stock News | |
|
Original source text
5.72K FollowersAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. |
|||
|
Saved
2026-06-13 17:40
1mo ago
Published
2026-06-13 12:59
1mo ago
|
Are You Looking for a High-Growth Dividend Stock? | FMP Stock News | |
|
Original source text
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns. CenterPoint Energy (CNP - Free Report) is headquartered in Houston, and is in the Utilities sector. The stock has seen a price change of 10.98% since the start of the year. The energy delivery company is paying out a dividend of $0.23 per share at the moment, with a dividend yield of 2.16% compared to the Utility - Electric Power industry's yield of 2.98% and the S&P 500's yield of 1.44%. Looking at dividend growth, the company's current annualized dividend of $0.92 is up 4.5% from last year. Over the last 5 years, CenterPoint Energy has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.33%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. CenterPoint's current payout ratio is 51%, meaning it paid out 51% of its trailing 12-month EPS as dividend. Looking at this fiscal year, CNP expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $1.91 per share, with earnings expected to increase 8.52% from the year ago period. From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. It's important to keep in mind that not all companies provide a quarterly payout. High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. With that in mind, CNP is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of #3 (Hold). |
|||
|
Saved
2026-06-13 17:32
1mo ago
Published
2026-06-13 12:00
1mo ago
|
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essenti | FMP Stock News | |
|
Original source text
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification.These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and Global Head of Research and Development. “What distinguishes INCA033989 is its potential to deliver disease control while targeting the biology that drives it. We remain on track to initiate our pivotal ET study by mid-2026 and are actively engaging regulators on a pivotal MF program.” Results in Patients with Myelofibrosis (MF) The safety, tolerability, and efficacy of INCA033989 in Type 1 and non-Type 1 patients with MF harboring a CALR mutation is being evaluated in two ongoing Phase 1 studies. Results demonstrate that INCA033989 delivers broad, clinically meaningful improvements across spleen volume, symptom burden and anemia in patients with MF. As a monotherapy and in combination with ruxolitinib, INCA033989 had a manageable safety profile and the majority of patients remained on treatment – no dose-limiting toxicities were observed, and a maximum tolerated dose was not reached. Monotherapy: INCA033989 was evaluated as monotherapy in patients who were resistant, refractory or intolerant to JAK inhibitor treatment after >12 weeks (JAK R/R/I), or ineligible to JAK inhibitor therapy. The dose escalation cohort evaluated INCA033989 from 24-3500 mg, and the dose expansion cohort evaluated 250 mg and 2000 mg. INCA033989 monotherapy demonstrated durable clinical benefit, with clinically meaningful improvements across spleen volume, symptoms and anemia across both JAK R/R/I and JAK ineligible patients. Spleen Volume Reduction (SVR): Rapid and robust spleen volume reductions were observed in patients, with 55% (38/69) and 39% (27/69) of patients achieving the best SVR25 and SVR35 reduction, respectively. At Week 24, 27% (17/62) patients achieved SVR35, including 47% (8/17) JAK ineligible and 20% (9/45) JAK R/R/I. Robust responses were observed in JAK ineligible patients regardless of mutation type (60% [6/10] Type-1 vs. 29% [2/7] non-Type 1). In JAK R/R/I patients, clinically meaningful reductions were observed in 31% (8/26) of Type-1 patients across all evaluated doses at Week 24, and 33% (1/3) of non-Type-1 patients evaluated at 2500 mg, the highest evaluated dose. Symptom Improvement: Improvements in symptoms were also observed in the majority of patients, with 53% of patients achieving at least a 50% best TSS reduction (TSS50). At Week 24, 32% of patients achieved TSS50, including 29% and 33% of JAK ineligible and JAK R/R/I patients, respectively. Anemia: Rapid and durable anemia improvements were observed in most patients, with anemia response occurring in 60% of evaluable anemic patients, and 52% of patients achieved a major anemia response. Improvements in anemia were observed across patients regardless of prior JAK exposure, including 63% of JAK R/R/I patients and 55% of JAK ineligible patients. Molecular: Consistent reductions in variant allele frequency (VAF) were observed across most patients, regardless of prior JAK exposure and mutation type, with 89% of patients achieving a reduction in whole blood mutCALR VAF (Type 1: 90%, Non-Type 1: 88%), and 81% of patients achieving a ≥25% reduction in mutCALR peripheral blood mononuclear cells (PBMC) from baseline (Type 1: 62%, Non-Type 1: 38%). INCA033989 was generally well-tolerated, with 84% (70/83) of patients remaining on therapy at the time of the data cut off. Treatment emergent adverse events (TEAEs) occurred in 92% (76) of patients, with 27% (22) of patients experiencing Grade ≥3 TEAEs, the most frequent of which were cytopenias. No dose-limiting toxicities were observed, and discontinuations due to TEAEs were limited (n=2). Combination therapy: INCA033989 (dose range: 70 to 2,500 mg) was evaluated in combination with ruxolitinib in patients with MF who experience a suboptimal response to ruxolitinib monotherapy. INCA033989 demonstrated additive, multi-domain clinical activity in patients when administered in combination with ruxolitinib. SVR: At Week 24, 55% (11/20) and 30% (6/20) of patients achieved SVR25 and SVR35, respectively. Symptom Improvement: 31% (5/16) of patients achieved TSS50 at Week 24. Anemia: Anemia response occurred in 35% (6/17) of evaluable anemic patients. INCA033989 in combination with ruxolitinib was generally well-tolerated, with 76% (16) of patients remaining on treatment at the time of the data cut off.In the combination arm (n=21), all patients experienced TEAEs. Grade ≥3 TEAEs were reported in 67% (14) of patients, most commonly anemia (33%). Translational data Clinical response occurred regardless of mutational complexity with SVR, anemia and molecular responses observed in patients with and without high molecular risk (HMR) mutations. 93% of patients with HMR had a reduction in whole blood mutCALR VAF, as did 88% of those without HMR mutations. A reduction in mutCALR-positive hematopoietic stem and progenitor cells (HSPCs) was also seen, indicating activity at the level of disease-initiating cells. "Patients with CALR-mutated MF have distinct disease biology and often respond poorly to available therapies, underscoring the need for treatments targeting the underlying driver of disease," said Claire Harrison, M.D., Professor of MPNs and Deputy Chief Medical Officer, Guy’s and St. Thomas’ NHS Foundation Trust. "What stands out in these data is that INCA033989 produced rapid and robust spleen, symptom and anemia responses, alongside reductions in mutCALR allele burden regardless of HMR mutations, pointing to activity at the level of the disease-initiating clone." Results in Patients with Essential Thrombocythemia Inpatients with ET, INCA033989 demonstrated rapid, deep and durable hematologic and molecular responses across both Type 1 and non-Type 1 CALR patients, supporting potential for disease modification in a population resistant or intolerant to prior cytoreductive therapy. Hematologic Response: Across doses, 70% (80/114) of patients achieved a complete hematologic response (CHR, platelet count ≤400 × 109/L and leukocytes <10 × 109/L) and 87% achieved complete or partial hematologic response (CHR/PHR, platelet count ≤600 × 109/L and leukocytes <10 × 109/L). 81% of patients with Type 1 mutCALR achieved a durable (>12 weeks) CHR at 750 mg and above; and 50% of patients with non–Type 1 mutCALR achieved a durable CHR/PHR at 2500 mg. The median time to onset of durable CHR was 2.1 weeks. Molecular Response and Disease Biology: ≥25% reduction in mutCALR VAF correlated with durable CHR (nominal P<0.0001, n=103). Of the patients who achieved a CHR and had ≥1 post-baseline VAF assessment, 73% achieved ≥25% reduction in VAF. Durable molecular response was observed in both Type 1 and non–Type 1 mutCALR. A reduction in mutCALR megakaryocytes was seen in both Type 1 and non-Type 1 patients treated with INCA033989 INCA033989 was well tolerated with 95% of patients remaining on treatment. The median duration of INCA033989 exposure was 8.1 months (range from 0.59 to 27.0 months). A low incidence of Grade ≥3 adverse events was observed (19%); the most common were neutropenia (4.4%) and lipase increase (3.5%). Grade ≥3 cytopenia TEAEs occurred in 6% (7/114) of patients; no Grade ≥3 thrombocytopenia TEAEs were observed. “In patients with ET who were resistant to or intolerant of prior cytoreductive therapy, INCA033989 resulted in rapid and durable normalization of platelet counts with accompanying molecular responses, with the majority of patients achieving a CHR," said John Mascarenhas, M.D., Professor of Medicine at the Icahn School of Medicine at Mt. Sinai and Director, Center of Excellence for Blood Cancers and Myeloid Disorders, The Tisch Cancer Institute. "As there are currently no mutation-specific treatments available for patients with ET, this approach is critically important for this high-risk patient population. These results provide a strong foundation for advancing INCA033989 into a registrational Phase 3 study." In November of 2025, INCA033989 was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy. A Phase 3 study of INCA033989 in mutCALR positive patients with ET who are resistant or intolerant to at least one prior cytoreductive therapy (EXCALIBUR-ET2, NCT07623200) is being initiated in mid-2026. More information regarding the EHA 2026 Congress can be found on the EHA website: https://ehaweb.org/connect-network/eha2026-congress. About Myeloproliferative Neoplasms (MPNs) and Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein folding. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs),1 a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells.2,3 Among two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases.4 In MF, it is estimated that 70-83% of CALR mutations in the U.S. are identified as Type 1, with 15-30% identified as non-Type 1.4,5 There are currently no targeted therapies for CALR mutations. Incyte is at the forefront of developing novel therapies for patients with mutCALR ET or MF that target only malignant cells, sparing normal cells, including INCA033989, a first-in-class, mutCALR-specific therapy. INCA033989 received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy. A Phase 3 study of INCA033989 in patients with ET with a Type 1 or non-Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy is being initiated (EXCALIBUR-ET2, NCT07623200). About the INCA33989-101 & INCA33989-102 Trials The clinical trial program for INCA033989 includes two multicenter, open-label Phase 1 studies, INCA33989-101 (NCT05936359) and INCA33989-102 (NCT06034002). The studies are evaluating the safety, tolerability and efficacy of INCA033989 in ~455 adult (≥18 years old) patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). The primary endpoint of the studies is measured by the number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and the number of participants with TEAEs leading to dose modification or discontinuation. Secondary endpoints include response rates, mean change of ET total symptom score, percentage of MF patients achieving spleen volume reduction, MF patient anemia response, mean change in disease-related allele burden and various pharmacokinetics measures. For more information on the studies, please visit: https://clinicaltrials.gov/study/NCT05936359 and https://clinicaltrials.gov/study/NCT06034002. About Incyte® Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity. To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the presentation of data for INCA033989; the potential for disease modification and the potential to benefit patients offered by INCA033989; expectations regarding ongoing and future clinical trials, including the timing of such trials; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s products; Incyte’s ability to achieve commercial success for its products, once approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements. 1 Raghavan, M., Wijeyesakere S.J., Peters L.R., Del Cid N. (2013) Calreticulin in the immune system: ins and outs. Trends in Immunology, 34(1):13-21. Link to source (https://www.cell.com/trends/immunology/abstract/S1471-4906(12)00131-7?_returnURL=https://linkinghub.elsevier.com/retrieve/pii/S1471490612001317?showall=true) 2 Nangalia J. Massie C.E., Baxter E.J., Nice F.L., et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Link to source (https://www.nejm.org/doi/10.1056/NEJMoa1312542?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0www.ncbi.nlm.nih.gov) 3 Klampfl T., Gisslinger, H., Harutyunyan A.S., et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25):2379-2390. Link to source (https://www.nejm.org/doi/10.1056/NEJMoa1311347?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0www.ncbi.nlm.nih.gov) 4 Salzman G. and Mullally A. (2026) Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. Blood, 147(12):1267-1277. Link to source (https://doi.org/10.1182/blood.2025028642) 5 Guglielmelli, P., Maccari, C., Sordi, B. et al. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer J. 13, 21 (2023). Link to source (https://doi.org/10.1038/s41408-023-00786-x) View source version on businesswire.com: https://www.businesswire.com/news/home/20260613021335/en/ |
|||
|
Saved
2026-06-13 17:24
1mo ago
Published
2026-06-13 12:25
1mo ago
|
4 Deeply Discounted BDCs Paying Us Up To 13% | FMP Stock News | |
|
Original source text
BDC concept is shown by businessman.getty Stocks are sky-high, but us contrarians are looking for dividend deals. And we found them in one forgotten corner of the Wall Street world. Here, we’re going to bank yields between 11% and 13% from BDCs. That’s right—up to 13%, for as little as 68 cents on the dollar. What does that mean? Well, these funds are trading at discounts as large as 32% off their book values. Where are we looking? We’re talking about business development companies, or BDCs. These are publicly traded firms that lend to mostly privately held companies—small and medium-sized businesses. The BDC business itself can be a bit of a cardiac kid. It’s all about getting paid back on these loans. The smart lenders can do very well over time. The sector is so potentially lucrative that it attracts some less-than-ideal managers—hence a bit of a shady reputation. But in these shadows is where we can find value. 2026 has been rough sledding for BDCs. There have been fears about the creditworthiness of the loans they’ve extended. It’s come to fruition—about one in four companies in the non-penny-stock BDC world have cut their dividends over the past few months. MORE FOR YOU Ugly, ugly, ugly. So why are we diving in this dumpster for dividends? Well, we’ve got three reasons to be intrigued. BDCs tend to own floating-rate debt, which means their income rises as short-term rates move up. And inversely, it drops as rates drop. High oil prices have put Federal Reserve rate cuts on hold indefinitely, and this has helped stabilize BDC income. Even after the dividend cuts we’ve seen, BDCs still remain one of the top sources of income for dividend investors. I mean, come on—where can we find yields like these?Hey—these stocks are rarely this cheap. Industry valuations haven’t been this low since COVID. As contrarian investors, we are stepping in to sort through the wreckage.So let’s talk about these dividend payers, dishing between 11.8% and 13% yields. We are looking for values here, not falling dividend knives, so these details matter. Cheap BDCs #1: Nuveen Churchill Direct Lending Corp (NCDL)Investing in business development companies often means hitching our wagons to the market’s most prominent asset managers. Take, for instance, Nuveen Churchill Direct Lending Corp. (NCDL), which bears the name of both fund manager Nuveen (the asset manager for TIAA) and BDC manager Churchill, a Nuveen affiliate. NCDL targets U.S. middle-market companies backed by private equity sponsors. It’s currently invested in 236 companies across 26 industries, with significant bents toward healthcare/pharmaceuticals and business services. It spreads out risk well, too—its top 10 holdings make up just 13% of the portfolio’s weight. Nuveen’s BDC does most of its financing via first-lien debt, and the lion’s share of that is floating-rate in nature—helpful in that higher interest rates can boost loan income, though they can also drive down loan demand. Nuveen Churchill Direct Lending has less than three years’ worth of trading under its belt, most of it just pinballing up and down. And because we’re in the midst of one of its sharp downturns, we can buy it for a cavernous 26% discount to its net asset value (NAV). But what would we be buying? A big dividend, sure—but one that’s been quietly shrinking since NCDL first hit the market. The 45-cent quarterly with a 10-cent supplemental on top? Gone. The supplemental dried up first. Then this year, the base got cut to 36 cents, with a 4-cent top-up thrown in as a consolation. Then that supplemental shrank to 2 cents in Q2. NCDL Dividend Ycharts What makes the underperformance and dividend difficulties surprising is that NCDL at least appears to be a solid operator. Non-accruals grew in the most recent quarter, but at just 1.3% of the portfolio at cost, so credit quality is excellent. (Non-accruals are loans that are delinquent for a prolonged period, usually 90 days.) It has a favorable fee structure thanks to waivers. Management is conservative and steeped in private-credit experience. Software exposure is low. Patient investors might eventually be rewarded. Until then, Nuveen’s BDC clearly isn’t treating the dividend with kid gloves. Cheap BDCs #2: Blackstone Secured Lending Fund (BXSL)Blackstone Secured Lending Fund (BXSL) leans on the rich resources of Blackstone (BX) and its Blackstone Credit & Insurance arm. And that brings up another important aspect of many BDCs: They’re not just lenders and stakeholders. BXSL’s 316 portfolio companies also enjoy the expertise and operational support of one of the world’s largest alternative credit platforms—and Blackstone Credit & Insurance doesn’t claw fees away from the BDC for the privilege. Blackstone’s BDC deals almost entirely in floating-rate first-lien debt. It likes larger companies in sectors with historically lower default rates. It’s plenty diversified, too, with its top holdings making up less than 20% of assets. However, while the portfolio is spread across nearly 40 industries, that top industry is a red flag. BXSL took a big step back in Q1. Non-accruals jumped to 4.7% at cost, while its net asset value declined by more than 2% quarter-over-quarter. Every other BDC seems to be hacking its dividend. Blackstone Secured Lending Fund’s has held at 77 cents. But it might just be late to the wake: Net investment income (NII) covered the payout this quarter, yet full-year 2026 and 2027 estimates are sliding toward levels that can’t sustain it. Shares have lost 20% of their value since July 2025, which has plumped up its static dividend to a yield of nearly 13%. But deterioration in net asset value has kept BXSL from falling into deep value territory—it currently trades at a decent 9% discount to NAV. Cheap BDCs #3: Carlyle Secured Lending (CGBD)Carlyle Secured Lending (CGBD) is yet another double-digit-paying BDC tethered to a well-known asset manager: Carlyle Group (CG). It invests in middle-market companies sponsored by PE. And its preferred deal type is floating-rate first-lien debt. But CGBD stands out for a much tighter portfolio of just 60 companies. And its financing is more spread out—first-lien debt makes up less than 85% of fair value; it also has mid-single-digit exposure to second-lien debt, equity investments and investment funds. Around this time last year, I wrote that CGBD’s first half of 2025 was a “train wreck.” It had just put together back-to-back earnings disappointments, experienced rising non-accruals, and failed to issue a supplemental dividend for the first time in years. Since then? Some ups, and some downs. The distribution was pared down even more. After a couple quarters of keeping the dividend level, CGBD in April announced a 12.5% cut to 35 cents per share. But the company has been putting together more promising results. While CGBD’s NAV declined by more than 2% during the first quarter, NII beat estimates, and non-accruals declined to just 1% of cost after portfolio company Alpine restructured its balance sheet. Carlyle Secured Lending also has a pair of joint ventures—Middle Market Credit Fund (MMCF) and Structured Credit Partners (SCP)—that are continuing to ramp. When I looked at Carlyle Secured Lending in mid-2025, it had been greatly underperforming other BDCs for months. It has continued to decline since then, but its red ink has been more in line with the industry. Still, that has dragged CGBD’s price down to a 32% discount to NAV, putting this Carlyle vehicle in the cheapest third of traded BDCs. Cheap BDCs #4: Barings BDC (BBDC)Barings BDC (BBDC) hasn’t always been tied up with manager Barings LLC. It was known as “Triangle Capital” for many years until August 2018, when the company rebranded, trying to put years of write-offs and dividend cuts in the rear-view mirror. It wasn’t just a brand refresh, either. The new name reflected its new relationship with global financial services firm Barings, which became an external advisor and went to work cutting out the portfolio’s rot. Today, Barings invests primarily in middle market companies owned by PE, though about 5%-15% of its investments are “non-sponsored” upper-middle-market and opportunistic middle-market deals, and another 5%-10% is exposure to Eclipse Business Capital and Rocade Capital—originators of middle market first-lien loans. BBDC has the lowest exposure to first-lien debt of the group, at just 70%. Roughly 20% of its deal mix is in equity, and the rest is scattered among second-lien and mezzanine debt, as well as other financing options. Last year, I was encouraged by a string of small quarterly supplementals—the company hadn’t made “top-up” specials in a decade. They didn’t last, but the regular dividend has remained intact, powering a 12%-plus yield. But that yield might have a clock on it. Earnings are pacing below the dividend, and the math only works as long as spillover earnings can bridge the gap. One helpful development just popped up about a week ago. Barings BDC terminated a credit support agreement, which will result in a $67 million payout by the end of the month—money the company can use to fund additional investments. And while BBDC has been a source of relative strength in 2026, down just a few percent versus double-digit declines for the BDC industry, it’s still dirt-cheap. This mega-payer currently trades at a 23% discount to NAV. Brett Owens is Chief Investment Strategist for Contrarian Outlook. For more great income ideas, get your free copy his latest special report: Your Early Retirement Portfolio: Huge Dividends—Every Month—Forever. |
|||
|
Saved
2026-06-13 17:22
1mo ago
Published
2026-06-13 11:39
1mo ago
|
Why Uranium Energy Stock Plummeted This Week | FMP Stock News | |
|
Original source text
Uranium Energy (UEC +3.76%) stock sank this week, ending the period down 12.7% even after seeing significant rebound momentum in Thursday and Friday's sessions. Meanwhile, the S&P 500 and the Nasdaq Composite both ended the week up roughly 0.7%.On June 9, Uranium Energy published its results for the third quarter of its current fiscal year -- which ended April 30. In addition to the market's negative reaction to the earnings report, the company also saw sell-offs connected to macroeconomic and geopolitical pressures. Image source: Getty Images. Investors weren't happy with Uranium Energy's Q3 report In fiscal Q3, Uranium Energy posted a net loss of $0.11 per share -- a performance that came in far worse than the average analyst estimate's call for a loss of $0.03 in the period. The business did not record any sales in the quarter. Along with the quarterly report, Uranium Energy said that it expected production to increase in the current quarter. Management also said that it expected a Class IV cost study to be completed in the first half of the next calendar year, potentially paving the way for an accelerated commercialization ramp. Today's Change ( 3.76 %) $ 0.40 Current Price $ 11.03 Macroeconomic and geopolitical news also weighed on the stock On Wednesday, the Bureau of Labor Statistics published its Consumer Price Index (CPI) report for May. The report showed overall CPI inflation of 4.2% and core CPI inflation of 2.9%. While the results were roughly in line with economists' forecasts, inflation also accelerated in the month. The inflation news was made more worrying by developments suggesting that the war with Iran was getting ready to ramp back up, but investors got good news on that front later in the week. Despite some conflict flare-ups, news subsequently emerged that the U.S. and Iran were close to making a peace deal -- and stocks rallied in response. While it looks like the two sides are poised to agree to basic terms to end the conflict, Uranium Energy's pre-revenue status means it could continue to see big swings in conjunction with macroeconomic and geopolitical news. Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. |
|||
|
Saved
2026-06-13 17:12
1mo ago
Published
2026-06-13 12:15
1mo ago
|
Verra Mobility Corporation (VRRM) Securities Fraud Class Action Lawsuit Filed; August 4, 2026, Lead Plaintiff Deadline | FMP Stock News | |
|
Original source text
Did you buy VRRM common stock between February 24, 2026 and May 26, 2026?Affected VRRM Investor Summary Who: Verra Mobilty Corporation (NASDAQ: VRRM) What: Securities fraud class action lawsuit filed Class Period: February 24, 2026 through May 26, 2026 Deadline to Seek Lead Plaintiff Status: August 4, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's continued growth in its Commercial Services business and contract with Avis Budget Group. Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options , /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Verra Mobility Corporation (Verra) (NASDAQ: VRRM) on behalf of those who purchased or acquired Verra common stock between February 24, 2026 and May 26, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Arizona and is captioned Otucu v. Verra Mobility Corporation, Case No.2:26-cv-03973 (D. Ariz.). Investors have until August 4, 2026, to file for lead plaintiff status. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Verra common stock and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at: Phone: (484) 270-1453 Email: [email protected] Website: https://www.ktmc.com/vrrm-verra-mobility-corporation-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=vrrm&mktm=PR There is no cost or obligation to speak with an attorney. VERRA MOBILITY CORPORATION CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Verra's optimistic plan for continued growth in its Commercial Services business was dependent on its relationship with Avis, and in particular obtaining a contract extension with Avis Budget Group; (2) Verra minimized concerns that major rent-a-car customers could replace Verra with in-house solutions or outsourced alternatives, making Verra's 2026 full year guidance increasingly unlikely to be met; and (3) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Why did Verra's Stock Drop? On May 26, 2026, Verra disclosed that the company had received a termination notice from Avis Budget Group regarding its contract, which becomes effective in September 2026. Verra further disclosed that it "expects the termination to reduce Commercial Services' 2026 annualized revenue by approximately $135 million to $145 million and 2026 annualized segment profit by approximately $120 million to $125 million, before taking into account expected cost reduction initiatives." Verra accordingly lowered its full year 2026 financial outlook. On this news, Verra's stock price fell $9.23 per share, or 70.6%, to close at $3.85 per share on May 27, 2026. On June 1, 2026, Verra announced that its President and Chief Executive Officer had been terminated as "the Board determined that a change in leadership [was] needed[.]" WHAT VRRM INVESTORS CAN DO NOW: File to be lead plaintiff by August 4, 2026. Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you. Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR VERRA MOBILITY CORPORATION INVESTORS: Verra investors may, no later than August 4, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Verra investors to contact the firm for more information. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. The complaint in this matter was not filed by KTMC. CONTACT: Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP |
|||
|
Saved
2026-06-13 16:55
1mo ago
Published
2026-06-13 11:12
1mo ago
|
MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH | FMP Stock News | |
|
Original source text
NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).If you currently own shares of Manhattan Associates stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=35966 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected]. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com |
|||
|
Saved
2026-06-13 16:50
1mo ago
Published
2026-06-13 11:30
1mo ago
|
Nu Holdings Stock Is Falling. Here's Why I'm Buying Shares. | FMP Stock News | |
|
Original source text
Few stocks are as misunderstood as Nu Holdings (NU +0.62%). The digital bank, which focuses on Latin America, is poised to generate substantial profits in the years to come, but it keeps being downgraded by Wall Street due to misinterpretations of its lending business.Shares are now down 37% from their highs, while revenue grew 42% year over year last quarter. Here's why I'm buying more shares of Nu Holdings after this recent dip. Increasing loyalty in Brazil As of last quarter, the company had 135 million customers, most of them in Brazil. Over half of adults in the country have an account with the digital bank, which aims to bring modern banking tools to those whom legacy banks previously disregarded, keeping them out of the financial system. At the same time, Nu's revenue from existing customers in Brazil is lower than that of the average bank. Management intends to change this by increasing product penetration through services like instant payments, lending, investing, and credit cards. Today's Change ( 0.62 %) $ 0.07 Current Price $ 12.16 For example, management just launched a premium credit card for wealthier customers called Nubank Ultravioleta, using a model similar to American Express' by adding services around credit card spending. This and other initiatives are why average monthly revenue per customer just hit a record of $15.90, growing 23% year over year. Investors are pessimistic about the digital bank's increase in nonperforming loans (NPLs) that are 15 to 90 days past due, which rose to 5% last quarter. However, this is a seasonality issue in Brazil and was only up from 4.8% in the same period a year ago. While you don't want to minimize this figure, it is the price of doing business with lower-income earners, which is factored into the interest rate charged on loans. Net income was up 41% year over year last quarter to $871 million. Image source: Nu Holdings. Hitting its stride in Mexico The company's expansion into Mexico is driving strong growth. It recently hit 15 million active customers in the country and is closing in on $1 billion in annual revenue, having launched its business in 2021. Mexico is much further behind Brazil in digital payments and credit card adoption, giving Nu Holdings the same runway it had in Brazil a decade ago. Market share in Mexico is still minuscule, but it is seeing huge customer adoption and steady growth in monthly revenue per customer. As these work in tandem, revenue in Mexico should continue to grow rapidly. Plus, its business just turned profitable in the country, which will turn it from a drag on net income over the last few years to a benefit over the next few. NU Net Income (TTM) data by YCharts; TTM = trailing 12 months. Returning capital to shareholders Over the past 12 months, Nu Holdings' net income was $3.2 billion. I expect further growth from the steady increase in revenue per customer in Brazil and the growth inflection underway in Mexico. The cherry on top is the company's rapid growth in Colombia and its planned expansion into the U.S. once it obtains a banking license here. This should help net income climb to $5 billion and even above $10 billion in the years ahead, especially once you factor in the operating leverage inherent in a scaled-up national bank with no overhead costs from physical branches. After its drawdown, Nu stock now trades at a market cap of $57 billion. To take advantage of this lower price, management is repurchasing stock in a new $1 billion program, which will help to reduce shares outstanding and grow earnings per share . A market cap of $57 billion is cheap for a business poised to eventually generate $10 billion or more in annual net income; you just need a time horizon longer than a year. That's why I am buying more shares of Nu Holdings stock. |
|||
|
Saved
2026-06-13 16:49
1mo ago
Published
2026-06-13 12:00
1mo ago
|
Can SoundHound Stock Reach $20 Again? Here's the Answer. | FMP Stock News | |
|
Original source text
As it sinks below $7, it's easy to forget that SoundHound AI (SOUN 1.21%) once traded above $20 in late December 2024 and early January 2025. Since then, however, SoundHound's stock price has been on a downward march, with shares slumping more than 30% in 2026.For the stock price to regain momentum, SoundHound needs to finalize an acquisition, turn that acquisition into a revenue generator, and move closer to profitability. It's possible for all that to happen, but it will take time. Image source: Getty Images. Finalizing and monetizing the deal SoundHound is in the process of acquiring LivePerson for an equity value of $43 million. The acquisition target offers artificial intelligence (AI) agents that businesses can use to answer website questions or reply to text messages. LivePerson reported revenue of more than $243 million in 2025, but it also reported a net loss of more than $67 million and has been financially struggling over the last several years. Still, SoundHound believes LivePerson's digital messaging offerings complement its voice-enabled AI solutions and projects that LivePerson will contribute $100 million in revenue in 2027. That would be quite a meaningful contribution, as SoundHound forecasts its 2026 full-year revenue will fall between $225 million and $260 million. Today's Change ( -1.21 %) $ -0.09 Current Price $ 6.92 What comes next? The LivePerson deal is expected to close in the second half of 2026. Once that is finalized, how well SoundHound integrates LivePerson into its operations can start to show up in the results. If SoundHound executes on that integration, investors will look for the AI company to move closer to profitability. If all that happens, the stock price can regain some footing and start working its way back up to that $20 range it was previously in. Since the acquisition still needs to close, this will take some time. SoundHound has upside, but the stock price may still keep sliding or trading sideways until the uncertainty over whether the LivePerson deal is a savvy move or a misstep clears up. Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends SoundHound AI. The Motley Fool has a disclosure policy. |
|||
|
Saved
2026-06-13 16:25
1mo ago
Published
2026-06-13 10:15
1mo ago
|
This Stock Is Down 40% in 2026. Here's What the Next 3 Years Could Realistically Look Like. | FMP Stock News | |
|
Original source text
Few stocks embody the promise and frustration of the nuclear energy renaissance quite like NuScale Power (SMR +3.29%).Back in 2020, NuScale became the first U.S. company to get a small modular reactor (SMR) design approved by the NRC. Since then, the company hasn't deployed a commercial SMR model in a real-world setting. And while electricity demands from artificial intelligence (AI) and data centers are expected to surge, NuScale has yet to emerge as tech's most obvious beneficiary. Today's Change ( 3.29 %) $ 0.32 Current Price $ 9.88 Over the next three years, a few possibilities could emerge for this first-mover in the SMR space. In the most bearish scenario, NuScale's projects continue to move slowly but steadily. It may begin conversations with utilities or industrial companies about another project, but most of its concentration will be on developing the two it currently has underway: the SMR plant in Romania and the deployment of 6 gigawatts (GW) of SMRs to the Tennessee Valley Authority (TVA). Image source: Getty Images. Cranking the bull dial to a more aggressive level, a three-year timeline could see NuScale's commercial partner, ENTRA1 Energy, secure customers in the data center space. In this scenario, the TVA project would be moving closer to completion, with meaningful revenue coming into view. Success there could also validate NuScale's technology, which in turn would open the door to additional deployments across the U.S. Regardless of the exact outcome, NuScale's first SMR is unlikely to come online for another few years. This means investors interested in NuScale will need to keep a watchful eye on its two developing projects, as their success could determine whether the company evolves into the major nuclear energy stock it's expected to become. Steven Porrello has positions in NuScale Power. The Motley Fool recommends NuScale Power. The Motley Fool has a disclosure policy. |
|||
|
Saved
2026-06-13 16:25
1mo ago
Published
2026-06-13 10:11
1mo ago
|
Nebius: Addressing The Current AI Constraints As It Grows | FMP Stock News | |
|
Original source text
5.42K FollowersAnalyst’s Disclosure: I/we have a beneficial long position in the shares of NBIS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. |
|||
|
Saved
2026-06-13 16:18
1mo ago
Published
2026-06-13 10:00
1mo ago
|
CAVA Group Looks Like A Buy (Technical Analysis) | FMP Stock News | |
|
Original source text
CAVA Group is a buy based on strong technical indicators despite poor valuation and profitability grades. Recent insider buying by C-suite executives and institutional accumulation reinforces the bullish outlook for CAVA. CAVA exhibits bullish price action, long-term momentum, and relative strength versus the S&P 500 since November 2025. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 10:32
1mo ago
|
SpaceX Shares Close Higher Post Historic $75 Billion IPO | FMP Stock News | |
|
Original source text
SpaceX's first day on the stock market transformed the startup into one of the world's most-valuable public companies, handed buyers of the IPO a 19% return and turned its founder Elon Musk into the world's first trillionaire. Bloomberg Tech Co-Host Ed Ludlow joined David Gura and Christina Ruffini on Bloomberg This Weekend to discuss. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 10:51
1mo ago
|
The Stock Market Survived the SpaceX IPO. What to Watch for Next. | FMP Stock News | |
|
Original source text
The S&P 500 held up just fine this past week, but a rush of offerings could signal trouble ahead. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 11:00
1mo ago
|
Why TD Securities anticipates even bigger days ahead for SpaceX | FMP Stock News | |
|
Original source text
watch nowThe most important dates for SpaceX haven't happened yet, according to TD Securities. Peter Haynes, the firm's head of index and market structure, suggests SpaceX's public debut is only a small part of the larger SpaceX timeline. He's urging investors to pay close attention to when SpaceX is added to key indexes — including the S&P Total Market Index, MCI Global Index, Russell Indexes and Nasdaq 100 early this summer. "Day 15 [after SpaceX goes public], which should be July 6… will be the day that Nasdaq rebalances the 100 Index to reflect SpaceX's IPO shares," he told CNBC's "ETF Edge" this week ahead of Friday's IPO. "Then from there, we're looking at when do indexes adjust for the additional shares that will be freely tradable down the road." In what Haynes called a "controversial decision," the S&P 500 Index Committee announced earlier this month that SpaceX will not be fast-tracked into the index, meaning the Elon Musk rocket maker must trade on the market for at least one year until it becomes eligible. "That leaves us with the other benchmarks and their rebalancing schedule," said Haynes. The decision means greater significance for upcoming index events, as many shares will become freely tradable and need to be reflected in the benchmarks, he says. SpaceX debuted at the Nasdaq at 11:46 a.m. ET on Friday. The stock surged more than 19% to close at $160.95 — its market cap exceeding $2 trillion. In a special note to CNBC after Friday's market close, Haynes wrote: "We take for granted that the infrastructure that supports the equity trading business always works. Today was a test of that infrastructure and in my opinion the industry passed the test." |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 11:03
1mo ago
|
SpaceX Stock Closed Up 19% in Its First Day Of Trading. Should Investors Buy, or Wait for the Hype to Cool? | FMP Stock News | |
|
Original source text
The debut is done. After 24 years as a private company, SpaceX (SPCX +19.17%) is now a public stock, and a volatile one. Shares priced at $135, opened at $150, traded as high as about $177, and closed at about $161 as of this writing -- a gain of about 19% on the day, with the stock continuing to climb in after-hours trading.That move values the rocket and satellite company at roughly $2.1 trillion, up from the $1.77 trillion the IPO price implied. It makes SpaceX one of the most valuable companies in the U.S. on day one, ahead of names like Meta Platforms and founder Elon Musk's own Tesla. So the interesting question is no longer whether the IPO would succeed. It clearly did. The question for anyone watching the ticker now is whether buying after a 19% pop is a disciplined move or a foolish chase. Here's a closer look at both sides. Image source: Getty Images. The bull case Start with Starlink, the satellite internet business that does most of the heavy lifting. SpaceX's initial public offering (IPO) disclosures show the connectivity segment, primarily driven by Starlink, generated about $11.4 billion in revenue in 2025, about 61% of the company's total, and it is the only segment producing consistent profits -- roughly $4.4 billion in operating income, or an operating margin of about 39%. And the subscriber growth has been steep. Starlink ended 2023 with about 2.3 million subscribers, a figure that climbed to about 8.9 million by the end of 2025 and surpassed 10 million by the first quarter of 2026. The company also has pricing levers it has barely started to pull. After letting average revenue per subscriber fall about 18% to roughly $81 a month between 2023 and 2025 to win volume, SpaceX raised some Starlink prices by up to $10 a month in May. Then there's the launch business, where SpaceX is dominant in a way few companies are dominant in anything. The company said its rockets accounted for more than four-fifths of all mass launched into orbit in 2025. That is the kind of position that is extraordinarily hard for a competitor to replicate, and it underpins the scarcity argument that helped drive demand for the shares. There is also the simple fact that there is no other public stock quite like this one. Investors who want exposure to commercial space, satellite broadband, and Musk's broader ambitions now have a single way to get it. That uniqueness arguably commands a premium on its own. Today's Change ( 19.17 %) $ 25.88 Current Price $ 160.88 The risks a day-one buyer takes on But a great business and a great stock are not the same thing, and the gap between the two has rarely looked wider than it does here. Start with valuation. At about $2.1 trillion, SpaceX trades at well over 100 times its 2025 revenue. For perspective, that is a multiple usually reserved for far smaller companies in the earliest innings of growth, not one of the largest companies in the country. And SpaceX isn't profitable on a consolidated basis. After folding in Musk's AI venture xAI, which it acquired in February 2026, the company posted a net loss of about $4.9 billion in 2025 and a loss of about $4.3 billion in the first quarter of 2026 alone. The AI segment is consuming Starlink's profits and then some. And a price like this leaves essentially no room for error. It assumes Starlink keeps compounding, the launch business stays unrivaled, and the unprofitable AI unit eventually turns into something that justifies the spending. There is also the matter of supply. SpaceX structured its lockup unusually, letting some shareholders begin selling portions of their holdings within weeks of the IPO rather than waiting the typical 180 days. Early shareholders can sell 20% of their shares around the company's first quarterly report covering the second quarter, with additional tranches unlocking later in the year. That means a meaningful wave of shareholder selling could arrive well before year-end, which could pressure the stock. And then there's the volatility a newly public megacap brings. Shares swung from up 11% to up more than 30% and back within a single session. The business is also closely tied to one founder who runs several other companies. So, post IPO, is SpaceX stock a buy? I don't think this is the moment to chase it. The business is remarkable, and Starlink alone may justify a massive valuation someday. But the current price already assumes a lot goes right, and the unusual lockup structure, combined with the stock's borderline egregious valuation, could create better entry points down the road. I'd rather be patient here than chase post-IPO gains. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 11:20
1mo ago
|
Cathie Wood Buys 3.3 Million SpaceX Shares On IPO Day | FMP Stock News | |
|
Original source text
ARK Invest, the investment firm run by Cathie Wood, scooped up nearly 3.3 million shares of SpaceX (SPCX) on Friday, the day Elon Musk's company went public.In the lead-up to the SpaceX IPO Wood and ARK Invest liquidated almost $280 million worth of stock positions in a week. On Friday, ARK Invest sold another roughly 948,000 shares of 13 different companies worth at least $48 million, according to company records. ↑ X NOW PLAYING 'It's Controversial': The Debate Over SpaceX's IPO Rule Change SpaceX went public on Friday at $135 a share in what was the largest IPO ever. Shares closed the day at 160.95, gaining 19.2%. ARK Invest And SpaceX Wood's ARK Innovation ETF (ARKK) did the bulk of the group's buying on Friday, gathering a total of 1,690,839 shares. That put SpaceX at 3.28% of the fund's portfolio. ARK Innovation trades a fraction lower so far this year. Wood's ARK Autonomous Technology & Robotics ETF (ARKQ) scooped up 736,442 shares, 2.65% of the fund's total portfolio. ARKQ has climbed 12.8% this year. The ARK Space & Defense Innovation ETFARKX ended the day with 538,341 SpaceX shares. That is 6.89% of its portfolio. ARK Space & Defense has advanced 16.6% in 2026. On the sell side, some of ARK's biggest stock sales Friday included: 80,536 shares of Advanced Micro Devices (AMD) valued at a minimum of $13 million; 98,835 shares of Roku (ROKU) worth at least $11.5 million; and 67,420 shares of the Chinese search engine Baidu (BIDU) valued at about $7.7 million, according to ARK Invest data. The Next Test For the Market, And SpaceX ARK Invest had sold Roku and Baidu stock earlier in the week as well. This was the first time this week the firm sold shares of AMD, though it had been actively selling the stock for several weeks since it surged in May, according to ARK Invest records. Wood has been a longtime backer of Musk and his various companies. Her firm had previously invested in SpaceX when it was still a private company through its ARK Venture Fund. The fund also had exposure to SpaceX through an investment in Musk's social media platform X. Musk's AI lab xAI bought X, before he eventually merged that company with SpaceX earlier this year. Prior to SpaceX's IPO, the company was the largest holding in the ARK Venture Fund, representing about 11.4% of its $1.035 billion in assets under management, according to the company's website. ARK Invest is also heavily invested in Musk's car company Tesla (TSLA). Tesla is the top holding in three different ARK Invest ETFs, according company documents. The firm owns 3.3 million shares of Tesla in four different ETFs valued at around $1.32 billion. Wood is so bullish on Tesla that ARK Invest famously has a 2029 price target of $2,600 for the stock, which would be about a 540% increase from Friday's closing price of 406.43. YOU MIGHT ALSO LIKE: Why This IBD Tool Simplifies The Search For Top Stocks Catch The Next Big Winning Stock With MarketSurge Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8 |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 11:23
1mo ago
|
Following through in Cleveland: A GeekWire trip report, plus data center ‘theater' and the SpaceX IPO | FMP Stock News | |
|
Original source text
by Todd Bishop on Jun 13, 2026 at 8:23 amJune 13, 2026 at 8:47 amScenes from GeekWire’s visit to Cleveland, where John Cook and Charles Fitzgerald spent several days reporting on the city’s comeback, including a stop at the abandoned Westinghouse light bulb factory where they recorded this week’s podcast. (Charles Fitzgerald and John Cook Photos) John Cook and Charles Fitzgerald spent several days in Cleveland this week, and they came back with a cautionary tale for Seattle: don’t assume the good times will last. But they also found inspiration: a city that’s coming back by getting its business, civic, and public leaders to row in the same direction. The GeekWire co-founder and the Seattle angel investor called into the GeekWire Podcast from an unlikely setting: an abandoned Westinghouse light bulb factory on Cleveland’s near east side, part of an industrial district called The Midline that’s being redeveloped for a new generation of jobs. The Cleveland trip closes a loop that opened in February, when Fitzgerald, a GeekWire contributing columnist, wrote a provocative piece warning that Seattle risked becoming the next Cleveland. Cleveland Mayor Justin Bibb joined the podcast to push back and make the case for his city, then invited the two to come see its comeback for themselves. This week, John and Charles took him up on it. Over several days, they met with Bibb, Ohio Gov. Mike DeWine, and a roster of developers, entrepreneurs, and civic and business leaders. What stood out, they say, was a city hustling and aligned around jobs and growth in a way Seattle no longer is. Their takeaway is blunt: Cleveland could eat Seattle’s lunch if Seattle keeps taking its prosperity for granted. For the full rundown of advice from those Cleveland leaders, see John’s previous story. Then we turn to the week’s news back home. The Seattle City Council voted unanimously for a one-year moratorium on new large data centers. Fitzgerald argues it’s political theater, since the big AI data centers were never coming to high-cost Seattle anyway, and says the real concern is the signal it sends about whether the city is open for business. And with the SpaceX IPO landing on Friday, Fitzgerald explains why he’s sitting it out. Subscribe to GeekWire in Apple Podcasts, Spotify, or wherever you listen. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 11:39
1mo ago
|
Why Musk Raced to Take SpaceX Public in the World's Biggest IPO | FMP Stock News | |
|
Original source text
As the gigantic space exploration startup barreled toward a public listing after 24 years as a private company, the urgency was apparent. The rush was driven by a canny strategy: go public before the US midterm elections, with a — mostly — pro-Musk president in charge; beat OpenAI and Anthropic to market to get in early on investors' appetite for AI-focused listings; and become a public company before Musk's 55th birthday at the end of June. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 12:00
1mo ago
|
SpaceX's Engineering Secret? A College Car-Racing Club | FMP Stock News | |
|
Original source text
Leaders at the space and AI company share ties to a Cornell University team where they honed their engineering skills. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 10:07
1mo ago
|
Apple Is Mostly Sitting Out the AI Spending Arms Race. With AI Stocks Selling Off, That Suddenly Looks Smart. | FMP Stock News | |
|
Original source text
Some of the technology world's biggest spenders had a rough week. Oracle sank by a double-digit percentage after pairing record quarterly results with plans to raise tens of billions of dollars in additional financing for its artificial intelligence (AI) data center build-out. Chip stocks fell hard, too, as investors questioned when all of this spending starts paying for itself.Some investors may think the best way to diversify away from these AI companies is to venture beyond tech. But I actually think one of tech's biggest names offers some good balance to stocks like this. I'm talking bout the $4.3 trillion iPhone-maker: Apple (AAPL 1.52%). Apple has been flagged by some investors in recent years as behind "behind" on AI as other tech giants spend far more to capitalize on opportunities in the AI era. But what if this is actually a strength? Image source: Getty Images. A spending gap in the hundreds of billions Apple's capital expenditures in fiscal 2025 (the period ended Sept. 27, 2025) totaled about $12.7 billion. Its mega-cap peers -- Microsoft, Alphabet, Meta Platforms, and Amazon -- combined to spend more than $400 billion on the same line item in calendar 2025. And the gap is set to widen. Amazon alone expects its capital spending to reach about $200 billion this year -- about 16 times what Apple spent in its most recent fiscal year. But this doesn't mean Apple is ignoring AI. The company is simply approaching it differently. At its developers conference on Monday, Apple unveiled its long-awaited Siri overhaul, powered by Alphabet's Gemini models under a partnership that reportedly costs about $1 billion per year, with the new software arriving this fall. Additionally, Apple's AI effort seems to run largely through its operating budget: research and development spending was $34.6 billion in fiscal 2025 -- nearly three times its capital expenditures -- and it climbed 33% year over year in the company's most recent quarter. And while peers borrow to build, Apple keeps handing cash back to shareholders. Alongside its fiscal second-quarter results in April (the period ended March 28, 2026), the company announced a new $100 billion share repurchase authorization and raised its dividend 4%. The quarter itself was Apple's best March quarter ever, with revenue climbing 17% year over year to $111.2 billion and earnings per share jumping 22%. "Our strong business performance during the March quarter generated over $28 billion in operating cash flow and drove new March quarter records for both operating cash flow and EPS," said Apple chief financial officer Kevan Parekh in the company's fiscal second-quarter earnings release. In other words, the cash that rivals are pouring into data centers is, at Apple, still flowing to shareholders. The case against patience Of course, there's a less flattering version of this story. Apple's revamped Siri runs on models built by a direct rival rather than on technology Apple owns. If AI assistants become the main way people interact with their devices, depending on Alphabet for that critical layer could prove costly. The rival, in effect, now sits inside the product Apple's customers talk to. And the stakes are enormous. Apple's installed base has surpassed 2.5 billion active devices. That base is a key part of the company's moat -- and it's also what could erode if a competitor's assistant becomes the one consumers actually prefer. Today's Change ( -1.52 %) $ -4.49 Current Price $ 291.14 What to watch Investors should watch two things from here. The first is how quickly users embrace the new Siri once it ships this fall. This could be revealed in any management commentary in the first quarterly earnings call following the release of Siri AI. The second main factor to watch is whether iPhone and services momentum holds up in the upcoming quarterly reports. Sustained double-digit growth in both iPhone and services revenue would suggest customers are buying into Apple's AI strategy. For now, I think the past week strengthens Apple's case. Restraint can look like timidity when AI infrastructure stocks are soaring. But when the market starts questioning the spenders' debt loads and cash burn, that same restraint starts to look like discipline. Sure, Apple may still need to prove it can deliver great AI experiences. But isn't letting someone else shoulder hundreds of billions in spending -- while you keep the customer relationship -- the kind of position most businesses dream of? |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 10:00
1mo ago
|
Big Challenges Ahead For Meta AI Chief Alexandr Wang After A Rocky First Year | FMP Stock News | |
|
Original source text
A year after Meta's $14.3 billion bet on Alexandr Wang, the company finally has its first proprietary AI model, but remains behind OpenAI, Anthropic and Google. High-profile hires from rival labs made headlines, but so did layoffs, key departures, and a year of widespread internal conflict and low morale. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 11:00
1mo ago
|
Why Meta Platforms Might Be a Good Buy Right Now | FMP Stock News | |
|
Original source text
Meta Platforms (META 0.14%) is dealing with a lot of pressure right now. The social media giant's stock is down more than 13% as of June 10, largely due to mounting regulatory issues and investors' growing skepticism about spending on artificial intelligence (AI). But long-term investors willing to look past recent turbulence may find that Meta is a worthy buy right now, given its low price.Today's Change ( -0.14 %) $ -0.82 Current Price $ 567.61 This isn't meant to discount the very real challenges Meta faces at the moment. Particularly in Europe, regulators are enforcing the Digital Markets Act, which threatens Meta's margins with fines and changes to data policies. On the spending side, Meta founder and CEO Mark Zuckerberg is committed to his AI infrastructure plan. Capital expenditures are substantial and perhaps hard to justify. After the failure of his Metaverse initiatives, investors and analysts are a bit more skeptical for good reason. Image source: The Motley Fool. On the bright side, Meta's business is still incredibly strong. Its advertising platform, spanning Instagram, Facebook, and WhatsApp, reaches nearly half the global population. That level of scale is not easily replicated or replaced. In the first quarter of 2026, advertising revenue exceeded $55 billion, with total Meta revenue reaching $56.3 billion. If Meta is successful with its AI ambitions, it could further boost the ad business in addition to wider adoption of its Llama models in other industries. Meta's stock is better priced than some of its peers. Even with a market cap topping $1 trillion, Meta's forward P/E ratio is just 18, and its PEG ratio is 0.82, which suggests the stock may be undervalued right now. Its price-to-sales, price-to-book, and enterprise value-to-revenue ratios are all in the single digits. No doubt, the company faces significant short- and intermediate-term headwinds, but if its AI strategy pays off and the advertising business continues to flourish, buying now while the stock is down is a solid move. Catie Hogan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool has a disclosure policy. |
|||
|
Saved
2026-06-13 16:08
1mo ago
Published
2026-06-13 12:00
1mo ago
|
Meta's MASSIVE workforce academy GUARANTEES jobs at finish line | FMP Stock News | |
|
Original source text
Meta President Dina Powell McCormick and CEO of mikeroweWORKS Foundation Mike Rowe join ‘Mornings with Maria' to discuss a new $115 million workforce initiative offering free training and guaranteed skilled-trade jobs. |
|||
|
Saved
2026-06-13 16:07
1mo ago
Published
2026-06-13 12:00
1mo ago
|
Alphabet: Buckle Up For What's Coming | FMP Stock News | |
|
Original source text
10.12K FollowersAnalyst’s Disclosure: I/we have a beneficial long position in the shares of GOOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Bohdan Kucheriavyi is not a financial/investment advisor, broker, or dealer. He's solely sharing personal experience and opinion; therefore, all strategies, tips, suggestions, and recommendations shared are solely for informational purposes. There are risks associated with investing in securities. Investing in stocks, bonds, options, exchange-traded funds, mutual funds, and money market funds involves the risk of loss. Loss of principal is possible. Some high-risk investments may use leverage, which will accentuate gains & losses. Foreign investing involves special risks, including greater volatility and political, economic, and currency risks and differences in accounting methods. A security’s or a firm’s past investment performance is not a guarantee or predictor of future investment performance. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. |
|||
|
Saved
2026-06-13 16:06
1mo ago
Published
2026-06-13 11:40
1mo ago
|
Citigroup: 6.3% Yielding Preferred Shares Are Interesting | FMP Stock News | |
|
Original source text
23.84K FollowersAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. |
|||
|
Saved
2026-06-13 16:05
1mo ago
Published
2026-06-13 06:33
1mo ago
|
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma | FMP Stock News | |
|
Original source text
TALVEY plus DARZALEX FASPRO with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months |
|||
|
Saved
2026-06-13 16:05
1mo ago
Published
2026-06-13 09:54
1mo ago
|
Disneyland and Disney World: New Lands, Rides and Summer Deals in 2026 and Beyond | FMP Stock News | |
|
Original source text
Summer is here, and Disneyland is continuing its year-long 70th anniversary, a celebration of the original Disney theme park opening its gates in 1955. Three new rides are also being built at the California Disney Parks, as well as a sprawling new Avatar area.Over at Walt Disney World in Florida, four new lands are being constructed right now, themed around villains, Pixar characters and more, and CNET got a behind-the-scenes look at some of the new areas. Here's everything you need to know about Disneyland and Disney World -- starting with offerings coming this summer and then exploring what's arriving beyond 2026. Watch this: Imagineers Share Secrets of Disney's New Ride Technology 09:28 Rock 'n' Roller Coaster starring The Muppets is now openWhile MuppetVision 3D closed last year to make way for an entire land themed around the Monsters Pixar movies at Hollywood Studios, the Muppets are being moved to the Rock 'n' Roller Coaster. That overlay didn't take long to complete -- Rock 'n' Roller Coaster Starring Aerosmith had its last day of operation on March 1, and the Muppets-themed version opens on Tuesday, May 26. "The legendary ride roars back to life with a rock-charged remix that drops guests straight into the middle of The Electric Mayhem's biggest night yet. With high-speed thrills, a pulse-pounding soundtrack, and a VIP list like no other, this reimagined attraction hits all the right notes," the Disney Parks Blog posted on April 16. CNET's Bridget Carey went behind the scenes to explore the technology used to update the Rock n Roller Coaster and bring the Muppets characters to life. Concept art of the Monsters, Inc. suspender coaster. Disney/PixarReplacing the old Muppets area of Hollywood Studios, meanwhile, Monstropolis -- home of the Monsters, Inc. movies, shorts and Disney Plus streaming series -- will feature Disney's first suspended roller coaster inside the city's laugh/scream factory. "The first time I saw Monsters, Inc., all I wanted to do was ride on one of those doors like Mike and Sulley," Disney Experiences Chair Josh D'Amaro said at D23 in 2024. "Remember in the movie how those claws grab the doors and hoist them up into the air to take them away? We're doing that too. And you're going along for the ride." This TikTok shows the design concept for the Monsters Inc. ride. MuppetVision 3D closed permanently a year ago, on June 8, 2025, but we don't expect Monstropolis to be complete for another year or two. Bridget also visited the Monsters area under construction, and you can watch her whole video on the new land below. Watch this: I Went Inside Disney's Monsters Land Under Construction. Here's What I Learned 01:25 Disneyland's 70th anniversaryDisneyland continues its celebration of its 70th anniversary, following its kick-off in May 2025, for much of the summer. Its last day is Aug. 9, 2026 -- after which the parks will transition to Halloween decor on Aug. 21, then the holidays on Nov. 18, before fully returning to its natural state in early 2027. There are many 70th anniversary shows to see, including the Paint the Night parade, Celebrate Happy Cavalcade and the Wondrous Journeys fireworks and projection show on the castle. Mickey and friends are also wearing 70th celebration outfits. You can catch 70th anniversary-themed merchandise, food and drink items as well as a projection show at Carthay Circle and a 50-foot sculpture of Sleeping Beauty Castle on the esplanade between Disneyland and California Adventure; you can also find decorations sprinkled throughout Downtown Disney, Main Street USA, Disney's hotels and even inside rides. Disneyland's Paint the Night parade. Disney ParksSoarin' Across America, coast to coast Disney ParksAt Disney's California Adventure and Disney World's Epcot, the Soarin' Around the World attraction is getting a US-themed makeover. Soarin' Across America will arrive on July 2, 2026, and will feature scenes, sounds and scents from more than a dozen cityscapes and scenic areas. Disney released a trailer starring Patrick Warburton, the original Soarin' narrator and pilot, in which he says we'll soon "sail across spacious skies" and may see "amber waves of grain" and "purple mountain majesties." It's part of Disney's celebration of America's 250th anniversary. Juneteenth at Disneyland Disney ParksOn June 19, Downtown Disney will host Disney on the Yard Presents Yardfest: Part of Celebrate Soulfully, which celebrates HBCUs, including performances by drum majors. This event on Juneteenth kicks off the Celebrate Soulfully: Summer Vibes celebration, which goes from June 19 until July 19 to celebrate Black music, food, art and culture. Concerts will be held on certain days at Paradise Gardens in California Adventure, as well as "special character encounters and live variety acts" on Fridays and Saturdays, per Disney. Bluey has arrived at Disneyland Disney ParksBluey and her family are now hosting a stage show and themed area at the original Disney park. Debuting in March, Bluey's Best Day Ever is located at the Fantasyland Theatre next to Mickey's Toontown, which has been transformed into Bluey's school classroom and grounds, including a gnome village and fairy garden. Bluey and her sister, Bingo, appear several times each day, along with actors and musicians, to "bring to life the popular music and games emblematic of beloved Bluey episodes." Those games will include "keepy uppy" and the "grannies," as well as appearances by Chattermax and Unicorse. There are also puzzles, games and photo ops throughout the Bluey area, and Disneyland is serving up Bluey-themed foods at Troubadour Tavern. The hugely popular Australian cartoon about a family of dogs is a worldwide hit, and Disney is slated to release a Bluey movie in 2027. (In the meantime, you can watch Bluey episodes and minisodes on Disney Plus.) Star Wars Galaxy's Edge: Old characters, new Mandalorian missions Disney ParksNew characters have begun roaming around the Star Wars-themed lands in Disneyland, as the area "expands its timeline" to include Luke Skywalker, Leia Organa and Han Solo. The original trio of Star Wars main characters arrived in Batuu on April 29 and are now interacting with guests and other characters. To help tie them in with the more modern Star Wars land, there are also new props, merch, graphics and music (featuring the legendary John Williams score) in Galaxy's Edge. "Black Spire Outpost will roll back in time several decades, thoughtfully introducing beloved characters from across the Star Wars timeline," the Disney Parks Blog announced in April. "Each era will be brought to life with the same care and attention to detail that the land was originally designed with, masterfully weaving together stories from across time and space in one location." Darth Vader has also joined the fun, and you can still see Ahsoka Tano, The Mandalorian, Grogu, Rey, Chewbacca and R2-D2. Over in Tomorrowland, Space Mountain has transformed into Hyperspace Mountain for a limited time. Disneyland (and Hollywood Studios at Disney World) has also now added Mandalorian and Grogu missions to the Millennium Falcon: Smuggler's Run ride in Star Wars: Galaxy's Edge, tying in with the release of The Mandalorian and Grogu in cinemas. The new missions launched on May 22. Discounted summer Disney ticketsDisneyland now has a Kids' Summer Ticket deal, with a one-day Park Hopper ticket costing $50 per child, ages 3 through 9. It can be used until Sept. 7. Disneyland is also adding (and removing) a Magic Key option: The Explore Key will replace the Enchant Key. All California residents will be able to purchase it -- not only Southern California residents. It will allow access on weekdays in June and July, which were blocked out for Enchant Key holders. The Explore Key costs $999, with a $99 down payment and 0% APR on repayments for 12 months. Disney said its "full value" can be unlocked in just four visits to the parks, thanks to Park Hopper admission, 25% off parking, Lightning Lane Multi-Passes and 10% off merchandise and dining. Disneyland's World of Color 70th anniversary show. Disney ParksFor what Disney World is calling Cool Kids' Summer, it's offering two free nights and two free theme park days when you buy a four-night, four-day Disney hotel and ticket package for a visit from May 26 through Sept. 15. You can also save up to 30% on some Disney hotels between May 1 and Oct. 4. Also part of Cool Kids' Summer is a free day at a Disney World water park (Typhoon Lagoon or Blizzard Beach) on your check-in day when staying at a Disney hotel between May 26 and Sept. 8; and a free dining plan for kids aged 3-9 when you buy a dining package for guests over 10 and a room at a Disney hotel. And if you have an iPhone, Apple has just announced that when the new iOS 27 drops later this year, you'll be able to use your Apple Wallet for Disney World tickets, reservations and events. California Adventure celebrates 25 yearsThe second Disney theme park built in Anaheim opened 25 years ago on Feb. 8, 2001. While the look of the park has changed a lot over those years, California Adventure has a few ways it's celebrating the quarter-century milestone: It's switching the Soarin' attraction back to Soarin' Over California until July 1; dressing Mickey Mouse and Minnie Mouse on Buena Vista Street with new outfits, featuring sun motifs like the one originally on the roller coaster; and offering anniversary-themed food items, merchandise and drinks. Disneyland expansion: Avatar area begins construction Concept art showing an aerial shot of the Avatar-themed area coming to Disneyland Resort. DisneyDisneyland is finally expanding after unveiling plans almost five years ago. The expansion is expected to take a couple of years to complete and will push the park's current boundaries past Downtown Disney and into the nearby parking lots. It'll also transform "a portion of the current Hollywood Backlot area," leading to the closure of the Monsters Inc. attraction permanently in 2027. The biggest part of the expansion will be adding an Avatar-themed land, based on the second film, The Way of Water, as well as Avatar: Fire and Ash. It will include a dark boat ride much like Pirates of the Caribbean, "taking guests all the way to the wide-open seas of Pandora." It follows the success of the world of Pandora, based on the original Avatar film, in Disney World's Animal Kingdom. Disney has no dates or details yet on when it'll be complete. Coming sooner than the Avatar land, however, is a new esplanade entry "experience" to replace the current walkway entry at the east side of Disneyland, as well as a new parking structure and pedestrian bridge over Harbor Boulevard. Construction on this begins in the fall. Concept art of the new pedestrian bridge that will cross Harbor Boulevard. DisneyA Coco ride is coming to California AdventureIt won't be launching this year, but construction has begun backstage at California Adventure to build a new dark ride. It'll be themed for the beloved Pixar movie Coco and populated by audio-animatronics. The Coco ride will be located in the area near Pixar Pier and Paradise Gardens, in what is primarily backstage areas for cast members currently. It'll have characters and music from the movies as you travel through the land of the dead with Miguel. Concept art for the new Coco ride. Disney/PixarTwo more Avengers Campus rides Avengers Campus already has two rides: Spider-Man Web Slingers and Guardians of the Galaxy. Soon, this will double as Disney builds two more Marvel attractions at California Adventure. "We're doubling the size of the land with two new attractions," a structural engineer said in a video posted to Walt Disney Imagineering's Instagram account on Feb. 26. The engineer showed off how the Avengers Infinity Defense structure is looking now, including its columns, foundations and a catwalk that will "support projectors, speakers and other types of show elements." Avengers Infinity Defense will see you assemble alongside the Avengers, battling King Thanos -- set in a multiverse -- featuring appearances by Black Panther, Ant-Man and Hulk. Concept art of the Avengers Infinity Defense attraction coming to California Adventure. DisneyStark Flight Lab, the second ride, will see you help test Tony Stark's latest tech. "In Stark Flight Lab, guests will sit in 'gyro-kinetic pods' and roll along a track before stopping in front of a giant robot arm," Disney said. "This robot arm will hoist you into the air where you'll make several high-speed maneuvers inspired by Iron Man and some other Avengers." Construction began in 2025, but no launch dates have been revealed yet. Villains Land at Disney WorldWhile it won't be ready in time for 2026, construction is well underway for Disney's first villains-themed area. Villains Land, which will celebrate all the classic baddies from Disney films, is coming to the Magic Kingdom at Disney World in Florida. Imagineers have been drawing inspiration from architectural structures in Paris and Barcelona -- like Gaudí's buildings in the latter -- to design Villains Land, Disney revealed during Destination D23 in August 2025. Concept art for the new Villains Land. Disney"Paris is a city full of classic Art Nouveau ... natural motifs and swirling designs there make nature appear to be 'cursed,' like magic has frozen it into place," Disney said on its Parks Blog. "Barcelona's art style is Modernisme, which has less natural patterns but gives the architecture an otherworldly, unnerving appearance." Villains Land, first teased during D23 2022, will be positioned on the other side of Big Thunder Mountain at the top left edge of the current Magic Kingdom map and will stretch around to where the Haunted Mansion is. Two major attractions are planned, along with dining and shopping. Still no word yet on when it'll open. First peek at Piston Peak Piston Peak National Park: the setting for the new Cars-themed land at Magic Kingdom. Disney ParksThe Rivers of America and Tom Sawyer Island at Disney World's Magic Kingdom have been closed and removed from the online map, as Disney works to construct a new land themed after Pixar's Cars movies. Cars Land, which was added to Disney's California Adventure back in 2012, remains extremely popular in the west, so it was only a matter of time before it was added to the eastern outpost. In an expansion of Frontierland -- which also includes Tiana's Bayou Adventure and Big Thunder Mountain Railroad -- Route 66 will feature a look inspired by the Rocky Mountains and the "American Frontier and its national parks." The Disney Parks Blog described the new area as "an awe-inspiring wilderness filled with towering trees, snowcapped mountains, breathtaking waterfalls, roaring rivers and impressive geysers." Disney Imagineers are "using a style of architecture called 'Parkitecture,' which was developed by the National Park Service to create structures that harmonize with the natural environment." Concept art of the Cars rally race attraction coming to Disney World. DisneyThere will be two attractions, one of which is a rally race. Pixar Chief Creative Officer Pete Docter and Imagineer Michael Hundgen spoke about the new ride vehicle for this, and you can see a TikTok of Imagineers testing out off-road vehicles in the Arizona desert to create what the ride will feel like. Each rally car will have its own personality, name and racing number, Docter said. "These are all things Lightning McQueen and Mater haven't experienced before, like racing over rocky terrain, ascending to mountain peaks and dodging around geysers -- how do you take these real-world elements and put a Cars spin on it?" Disney Parks said in a previous blog post. While construction has begun and Disney has even released a map showing what the land may look like (geysers shooting water, a running river, an off-road rally track, mountains, a visitor's lodge, a Ranger HQ and walking trails), we don't expect Piston Peak to open until at least 2027 or 2028. Tropical Americas Land at Animal Kingdom Concept art of Tropical Americas. DisneyAnimal Kingdom's DinoLand USA area is no more, with the area on the Disney World map now a blank sea of grass as Disney slowly builds out the new Tropical Americas Land. Construction began in the fall of 2024, with TriceraTop Spin and the midway area closing down in January 2025. The Dinosaur ride remained open until Feb. 1 this year, but has since closed its doors as it's transformed into a new Indiana Jones ride through a Maya temple (a relatively easy overlay since Disneyland's Indiana Jones reportedly follows almost exactly the same ride track as Disney World's Dinosaur). The Pueblo Esperanza area will be themed like a South American village, with an Encanto-themed attraction, where you get to explore Antonio's rainforest room inside the Casita, as well as a huge quick-service dining location, a fountain and a carousel. Tropical Americas is planned to open in 2027. Disney Cruise Line: New shipsDisney has been all in on launching cruise ships over the last few years, including the Disney Wish in 2022, the Disney Treasure in 2024 and the Disney Destiny in 2025. The Disney Adventure sailed on its maiden voyage from Singapore on March 10, the first of four new ships set to embark soon. Disney's next cruise liner, the Disney Believe, was unveiled by new CEO Josh D'Amaro on March 18. "The Disney Believe will bring to life the magical worlds of Encanto and Frozen, the wishing wells of Snow White and the Seven Dwarfs, and the depths of the sea with Moana and The Little Mermaid," Disney said. The Disney Believe is expected to set sail in late 2027. The other ship names and destinations have yet to be revealed, but they're expected to sail before 2031. Watch this: Imagineers Share Secrets of Disney's New Ride Technology 09:28 Everything else new at Disneyland and Disney World in 2026Here's what else is new and coming soon to the theme parks: A 3D-printed boat was added to the Jungle Cruise ride in January.Buzz Lightyear's Space Ranger Spin at the Magic Kingdom has new ride vehicles with video monitors and two handheld blasters featuring always-on lasers in two different colors (so you can finally see which laser is yours). It also got a new opening scene starring Buddy the friendly robot, and static Z targets light up when you hit them. The ride reopened on April 8.Big Thunder Mountain Railroad reopened on May 3 at Magic Kingdom after a lengthy refurbishment.Disney World's water park Blizzard Beach reopened on Feb. 15, and Typhoon Lagoon reopened on May 12.Kids' summer shows at Disneyland include Disney Friends Dance Party at Hollywood Land in Disney California Adventure, and Stitch's Interplanetary Beach Party Blast at Tomorrowland Terrace in Disneyland.Bluey and Bingo meet-and-greets are happening at Disney World at the Conservation Station at Animal Kingdom as part of the Cool Kids' Summer celebration, which goes until Sept. 8.Cinderella Castle at Magic Kingdom is being repainted in its original theme colors: gray, cream, blue and gold.From July, you'll be able to book a wedding at the Haunted Mansion in Disneyland. Weddings will be hosted at the courtyard right outside the mansion's front doors. The area can seat up to 25 guests. However, it doesn't include thematic midnight ceremonies -- you can only host your wedding there in the early morning before park opening. Other new Disneyland wedding venues include the Magnolia Park Gazebo (right outside Tiana's Palace), Magnolia Park Terrace (right outside the new Haunted Mansion queue) and Fantasy Faire Garden (opposite the castle).Following the release of the Walt Disney animatronic at Disneyland, Disney announced that a similar animatronic will be added to Disney World's Carousel of Progress at Magic Kingdom in a new introductory scene to the ride. Concept art of the overhauled version of Buzz Lightyear's Space Ranger Spin, which will have two different colored lasers in each ride vehicle. Disney/Pixar |
|||
|
Saved
2026-06-13 16:04
1mo ago
Published
2026-06-13 09:56
1mo ago
|
Starbucks Stock Nearing 52-Week High: Buy, Sell or Hold? | FMP Stock News | |
|
Original source text
At $102.28, Starbucks (NASDAQ:SBUX | SBUX Price Prediction) is a Hold. |
|||
|
Saved
2026-06-13 16:03
1mo ago
Published
2026-06-13 04:50
1mo ago
|
Why London BTC is building a Nevada gold portfolio - ICYMI | FMP Stock News | |
|
Original source text
London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) is expanding its Nevada gold portfolio as part of a strategy designed to complement its core Bitcoin treasury and mining operations. In this interview with Proactive, chief executive Hewie Rattray discusses the rationale behind the company's latest project acquisitions and how management sees gold supporting long-term Bitcoin accumulation. Watch the interview below, followed by the full transcript.Proactive: Hello, you are watching Proactive. I'm joined by Hewie Rattray, the CEO of London BTC Company. Hewie, very good to speak with you. You've moved remarkably quickly from announcing a US gold hedge strategy to staking two Nevada projects within days. Why was now the right time to add gold to the story, and what gap does it fill alongside your Bitcoin treasury and mining operations? Hewie Rattray: Currently, with the Bitcoin market as it is and many investors taking a risk-off approach, we wanted to pursue another strategy that made sense alongside Bitcoin. Gold is a natural fit for us in Nevada because most of the board has significant experience in the sector. This is our second project under the gold strategy and there will be more to come. We're investing capital into the strategy and believe investors will understand the relationship between Bitcoin and gold and why it makes sense. Proactive: Both projects sit near major gold operations and appear to have seen little modern exploration. What was it about Huntington-Whitman and Amonett-Frank that convinced you these were opportunities worth pursuing? Hewie Rattray: These areas hosted producing mines historically and are located near major producers operating today. They haven't been tested with modern exploration techniques. Gold has rallied strongly over the last year, improving economic viability in these regions. We want to capitalise on that opportunity and determine the best route to monetisation, whether through infrastructure development, royalties or other arrangements. We know there is gold in the ground and now it's about identifying the optimal strategy. Proactive: The rock-chip grades at Amonett-Frank are eye-catching, but investors know early-stage projects come with risk. What milestones should they focus on over the coming months? Hewie Rattray: Staking is a low-cost way to secure exposure and should be viewed as a useful indicator rather than proof. Several milestones are coming over the next few months that will help validate the assets. Investors should focus on the results and management commentary to understand how we plan to develop these opportunities. Proactive: Should investors expect London BTC to remain primarily a Bitcoin miner and treasury company with a gold hedge, or do you see an opportunity to build a platform offering exposure to both digital and physical stores of value? Hewie Rattray: We're still a Bitcoin-first company, but we're actively building a differentiated listed platform that provides exposure to scarce assets. The ultimate goal of the gold strategy is to monetise those assets and reinvest the proceeds into Bitcoin. We're seeking a different route to building our Bitcoin balance sheet rather than simply raising capital and purchasing Bitcoin directly. There are multiple ways to monetise these assets and rotate capital back into Bitcoin. Proactive: What should investors be watching for next? Hewie Rattray: We're going to continue executing the strategy we've demonstrated this week. There are additional projects under review and we'll announce developments when appropriate. We expect to be very active throughout the summer and anticipate this being our busiest period in around a year. It's an exciting time for the company. Proactive: Hewie, thank you very much for your time today. |
|||
|
Saved
2026-06-13 16:03
1mo ago
Published
2026-06-13 04:59
1mo ago
|
Arizona Gold & Silver launches Silverton drill program – ICYMI | FMP Stock News | |
|
Original source text
Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF, FRA:A9J0) earlier this week announced the launch of a new drill program at its Silverton Project in Nevada, targeting a large antimony system that management believes could also enhance the prospectivity of a deeper Carlin-style gold deposit.Speaking with Proactive, CEO Mike Stark said the company has initiated a 27-hole reverse-circulation drilling campaign designed to test a sizeable antimony target measuring roughly 900 metres in length and 400 metres in width. Stark said Silverton, located east of Tonopah, was initially acquired and explored for its potential to host a Carlin-style gold deposit. However, recent work has highlighted an additional opportunity in antimony, a critical mineral that has attracted growing attention from governments and industry participants due to supply chain concerns. According to Stark, surface sampling conducted in October returned encouraging results from 28 samples, with grades reaching as high as 7.9% antimony. He said the upcoming drilling program is intended to determine whether those surface values extend across a meaningful area and could support the definition of a substantial mineralized system. The CEO noted that antimony prices have risen above US$60 per pound, reflecting strong demand and limited supply. He added that the US government is actively seeking secure domestic sources of critical minerals, potentially increasing the strategic value of projects capable of supplying antimony within North America. A key catalyst for investors will be the results of the current drill campaign. Positive intersections could not only confirm the scale of the near-surface antimony target but also improve the geological case for a deeper gold system. The initial drilling will focus on shallow depths of approximately 30 to 45 metres, reflecting the near-surface nature of the antimony mineralization identified through sampling. The program is expected to be completed within approximately six weeks. Looking ahead, Arizona Gold & Silver plans to case three drill holes so they can be used in a future core drilling program targeting an IP anomaly at depth. That future work would test the potential Carlin-style gold target approximately 900 feet below surface. Investors will now be watching for assay results from the current campaign, which could provide important insight into both the antimony opportunity and the broader exploration potential of the Silverton Project. |
|||
|
Saved
2026-06-13 16:01
1mo ago
Published
2026-06-13 10:00
1mo ago
|
Dividend Safety Check: CNBS and Income in the Cannabis Sector | FMP Stock News | |
|
Original source text
© Westlight / Shutterstock.comThe Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) sits at the awkward intersection of a thematic sector bet and an income wrapper. CNBS holds a concentrated basket of cannabis operators, and its distribution profile is shaped almost entirely by one name: a struggling REIT. With CNBS trading near $29 and an expense ratio of 0.76%, anyone considering CNBS for income needs to understand that the fund’s payout sustainability hinges on a single tenant-stressed cannabis landlord rather than on a diversified pool of dividend payers. Where the Income Actually Comes From Cannabis is a growth-stage sector, and that shows up in CNBS’s holdings. Of the four named positions, only one writes a meaningful check to shareholders. Innovative Industrial Properties (NYSE:IIPR) pays $7.60 annually, currently yielding roughly 12.3% on its own share price. The three large multi-state operators in the fund, Trulieve, Green Thumb, and Cresco Labs, pay nothing. Green Thumb returns capital exclusively through buybacks, repurchasing roughly 29 million shares for about $200 million since September 2023. That is shareholder-friendly, but none of it flows into CNBS distributions. What that means in plain terms: CNBS’s distribution rides on IIPR. If IIPR cuts, the fund’s payout shrinks materially. The IIPR Problem IIPR’s dividend has held steady at $1.90 per quarter for eight straight quarters, and the company has never cut. That track record matters. The issue is current coverage. In Q1 2026, IIPR reported AFFO of $1.88 per share against a $1.90 dividend, an AFFO payout ratio of roughly 101%. The dividend is, by a hair, exceeding the cash metric it is supposed to be funded from. Operating cash flow of $56 million barely covered the $54.9 million quarterly dividend, and for full-year 2025, OCF of $198.2 million fell short of $219.5 million in distributions. That is the definition of a stretched payout. The pressure is real. Tenants PharmaCann, 4Front Ventures, and Battle Green are in default, costing about $6.9 million in Q1 revenue, and the top 10 tenants account for 67% of base rent. IIPR also faces $291.2 million in unsecured notes maturing in May 2026, with CEO Alan Gold pursuing nearly $130 million in additional debt to refinance. Interest expense jumped to $6.4 million from $4.5 million year over year. There is one offset worth naming. IIPR’s up-to-$270 million IQHQ life-science investment is already generating $5 to $6.7 million per quarter in interest and dividend income, providing diversification away from cannabis tenants. And the April 2026 reclassification of medical cannabis to Schedule III removes the 280E tax burden for IIPR’s tenant base, which should improve their ability to pay rent. Price Performance and the Total Return Picture Any income discussion has to confront what CNBS has done to capital. Shares are up roughly 97% over the past year on rescheduling optimism, but the five-year picture is brutal: down about 86%. The underlying names tell the same story. Cresco Labs trades at $0.82, down roughly 93% over five years, and burned $13.2 million in free cash flow last quarter while servicing a $325 million term loan at 12.5%. The Verdict CNBS functions as a growth and regulatory-catalyst vehicle that happens to carry a distribution. Its distribution is a byproduct of holding IIPR, whose payout is currently uncovered by AFFO, threatened by tenant defaults, and pressured by a near-term debt refinancing. Polymarket traders currently assign just a 27% probability of full rescheduling by year-end 2026, so the regulatory rescue is not a sure thing on any near-term timeline. Owning IIPR directly offers investors who want cannabis exposure with a side of income a more transparent 12.3% yield, with the risks unfiltered by a fund wrapper. CNBS makes sense for thematic upside, with the distribution treated as a secondary consideration rather than a reliable income stream. |
|||
|
Saved
2026-06-13 15:57
1mo ago
Published
2026-06-13 10:11
1mo ago
|
Rare Buying Opportunity: Discounted Elite Dividend Machines With Major Macro Tailwinds | FMP Stock News | |
|
Original source text
Whenever I can buy an elite dividend machine with major macro tailwinds at a big discount, I jump at the opportunity. I list 3 of these rare compelling buying opportunities in this article. I also detail their investment theses. |
|||
|
Saved
2026-06-13 15:56
1mo ago
Published
2026-06-13 10:03
1mo ago
|
Lemonade Is Betting Everything on AI Insurance. Should Investors Follow? | FMP Stock News | |
|
Original source text
Companies that are innovating with artificial intelligence (AI) have been rewarded by the market, even though volatility hasn't faded. Shares in Lemonade (LMND +0.54%) might be down 20% in 2026 (as of June 11), but they have skyrocketed 194% in the past three years.That's a notable winning streak that can catch the attention of the investment community. This fintech stock is betting it all on AI insurance. Should investors buy shares today? Image source: The Motley Fool. Growth is not an issue for Lemonade The insurance industry is one of the oldest. Lemonade wants to bring it into the digital age. By integrating AI and machine learning capabilities throughout its organization, the business aims to provide its customers with a superior experience. Lemonade operates with a direct-to-consumer and purely digital model. The company says that individuals can sign up for a new policy (using a tool called AI Maya) in as little as 90 seconds. For existing policyholders, more than half of claims are paid out instantly (using AI Jim). There is minimal human intervention, as these processes are increasingly being automated. The growth trends prove that this business model has found remarkable product-market fit. During the first quarter (ended March 31), Lemonade reported a 23% year-over-year jump in customers to over 3.1 million, while its in-force premium surged 32% to $1.3 billion. Revenue was up 71%. Lemonade started out in 2015 by only offering renters and homeowners insurance. Today, its product suite has expanded to include car, pet, and term life insurance. Besides the U.S., it serves customers in Europe. Today's Change ( 0.54 %) $ 0.31 Current Price $ 57.49 Waiting for consistent profits While Lemonade stock caters to growth investors, it has not yet reached profitability. The net loss was a reported $165.5 million in 2025. The consensus view among analysts is that Lemonade will generate positive GAAP net income in 2028. Investors will need to be patient. However, the business is making progress. The net loss ratio, which Lemonade defines as the "ratio of losses and loss adjustment expense, less amounts ceded to reinsurers, to net earned premium," improved to 63% in Q1 from 82% in the year-ago period. Management is forecasting positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in the fourth quarter, which would be a first for the company. These are encouraging trends. The leadership team must continue to run the business with operational and risk discipline to become profitable sooner rather than later. Efficiency gains from AI, demonstrated by surging in-force premium per employee, help to control costs. As is the case with any early-stage and unprofitable company, Lemonade presents investors with a high-risk/high-reward opportunity. Only those who are comfortable with more uncertainty should consider buying shares. Even then, perhaps Lemonade should be limited to 1% of a diversified portfolio. |
|||
|
Saved
2026-06-13 15:53
1mo ago
Published
2026-06-13 11:15
1mo ago
|
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting | FMP Stock News | |
|
Original source text
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing therapies and a novel treatment option for patients who become resistant to type I JAK2 inhibitors. Lilly recently added this program to its pipeline following the completion of the acquisition of Ajax Therapeutics, Inc.These data will be highlighted in an oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting taking place in Stockholm, Sweden (Abstract number: S218) and featured in the meeting's press program. "Patients with myelofibrosis who have been previously treated with an existing type I JAK2 inhibitor face very limited treatment options, highlighting an urgent need for new therapies," said John Mascarenhas, MD, professor of medicine, Icahn School of Medicine at Mount Sinai and principal investigator of the AJX-101 study. "These early clinical findings suggest that selective targeting of the type II conformation of JAK2 may provide a differentiated approach. With an encouraging safety profile, meaningful spleen size reduction, symptom improvement, and decrease in underlying mutant disease burden, these data, while early, point to the potential to meaningfully impact treatment options for people with certain myeloproliferative neoplasms." AJX-101 is the first clinical trial to evaluate a type II selective JAK2 inhibitor in patients with myelofibrosis. The trial enrolled 23 patients across five dose levels (25, 50, 75, 100, and 125 mg once daily) in its dose escalation phase. Patients had received a median of two prior therapies, and all had previously received a type I JAK2 inhibitor. The trial enrolled patients across all major myelofibrosis subtypes and driver mutations. AJ1-11095 demonstrated responses across the standard efficacy endpoints of spleen volume reduction and symptom improvement.1 The SVR35 rate, a reduction in spleen volume of at least 35%, was observed as best response in 70% of patients. The TSS50 rate, indicating at least a 50% improvement in symptom burden, was also seen in 70% of patients at week 12. In addition, reductions in driver mutation variant allele frequency (VAF) were observed in 21 out of 23 patients. Among the 17 patients who reached week 24 of treatment, 59% saw a reduction of 20% or greater and 35% saw a reduction of 50% or greater, including JAK2, MPL, and CALR type 1 and type 2 mutations. VAF reductions are uncommonly observed with existing type I JAK2 inhibitors.2 The overall safety profile for the medicine was generally manageable. No dose-limiting toxicities were observed, and most patients enrolled in the dose escalation phase remain on study (78%).3 The most common treatment-emergent adverse events across all dose levels included anemia, dysgeusia, decreased platelet count, and increased alanine aminotransferase. "The depth of response seen across spleen, symptoms, and VAF from these early phase results is in excess of what has been seen historically in this disease setting," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "These data provide clear proof of concept for what this selective type II JAK2 inhibitor could mean for patients with myelofibrosis and shed light on the conviction we brought to the acquisition of Ajax. With this program now officially part of Lilly's pipeline, we are committed to rapidly advancing it through clinical development and further exploring its potential to meaningfully improve outcomes for people with myeloproliferative neoplasms across a range of disease settings." AJ1-11095 is currently being evaluated in an expansion cohort in second-line myelofibrosis, with plans to investigate in patients with high-risk polycythemia vera and those with myelofibrosis who have not yet received a JAK2 inhibitor. Details on the AJX-101 trial can be found by visiting clinicaltrials.gov. About AJ1-11095 AJ1-11095 is an investigational, oral, first-in-class type II JAK2 inhibitor. AJ1-11095 is designed to bind JAK2 in its inactive conformation — an approach intended to more completely suppress the aberrant signaling that drives myelofibrosis, in contrast to currently approved JAK2 inhibitors that bind JAK2 in its active state. AJ1-11095 demonstrated superior activity compared to ruxolitinib in preclinical models of myelofibrosis. AJ1-11095 is currently being studied in AJX-101, a global, open-label, multicenter, Phase 1 study in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have previously been treated with a type I JAK2 inhibitor, NCT06343805. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY © Lilly USA, LLC 2026. ALL RIGHTS RESERVED. Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about AJ1-11095 as a potential treatment for adults with myelofibrosis and other myeloproliferative neoplasms, and the timeline for future studies, regulatory submissions, presentations, and other milestones relating to AJ1-11095 and the AJX-101 clinical program, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned or that future study results will be consistent with study results to date. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. _________________________________ 1 May 28, 2026 data cutoff 2 Meyer SC et al Cancer Cell 2015: 28:P15-28 3 May 12, 2026 data cutoff SOURCE Eli Lilly and Company |
|||
|
Saved
2026-06-13 15:52
1mo ago
Published
2026-06-13 10:30
1mo ago
|
3 Semiconductor Stocks to Buy While They Are Down in June | FMP Stock News | |
|
Original source text
Semiconductor leaders are coming into June 2026 with a fresh dent in the chart after a spring run that pushed valuations to uncomfortable levels. The trigger was Broadcom’s Q3 AI revenue guide, which came in at $16 billion versus analyst expectations near $17.2 billion and dragged the entire AI chip complex lower.The PHLX chip index dropped 10% on June 5, the deepest one-day loss since March 2020, wiping roughly $1.3 trillion in sector market value. The structural AI infrastructure thesis is unchanged. Here are three names worth researching while they trade below recent highs. This infographic presents a detailed financial overview for NVIDIA, AMD, and Broadcom as of June 10, 2026, highlighting their recent market performance, analyst targets, and key financial drivers amidst recent pullbacks. NVIDIA (NVDA) NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) trades at $200.42 as of June 10, sitting 26% below its 52-week high of $236.26. The stock is down 9% over the past month and down 7% over the past week, even as it remains up 39% over the past year. The bull case is the Q1 FY27 report on May 20, 2026. Revenue hit $81.615 billion, up 85% year over year, with non-GAAP EPS of $1.87 versus a $1.7738 estimate. Data Center revenue reached $75.246 billion, up 92% YoY, with Networking up 199%. Free cash flow printed at $48.554 billion, and management guided Q2 to $91.0 billion in revenue at a 75% non-GAAP gross margin. CEO Jensen Huang framed the demand backdrop bluntly: “The buildout of AI factories, the largest infrastructure expansion in human history, is accelerating at extraordinary speed.” Analyst sentiment skews heavily bullish, with 48 Buy and 10 Strong Buy ratings against just 1 Sell, and a consensus target of $298.42. Risk: The Q2 guide explicitly assumes zero Data Center compute revenue from China, and management flagged a substantial cash tax increase in Q2. Export controls remain the swing factor. Advanced Micro Devices (AMD) Advanced Micro Devices (NASDAQ:AMD) closed at $452.40 on June 10, down 17% over the past week from $542.52. Shares sit 12% below the 52-week high of $546.44, though the name remains up 111% year to date. The recent gap from highs is meaningful even after the strong YTD run. Q1 2026 revenue came in at $10.253 billion, up 38% YoY, with non-GAAP EPS of $1.37 versus a $1.29 estimate. The Data Center segment carried the quarter at $5.775 billion, up 57% YoY, and free cash flow expanded 253% to $2.566 billion. Management guided Q2 to roughly $11.2 billion in revenue, about 46% YoY growth, at a 56% gross margin. CEO Lisa Su pointed to the MI450 pipeline: “Customer engagement around MI450 Series and Helios is strengthening, with leading customer forecasts exceeding our initial expectations.” The signed agreement to deploy up to 6 gigawatts of AMD Instinct GPUs with Meta, including a first 1-GW custom MI450 build, anchors the multi-year thesis. Risk: Valuation runs hot at a P/E near 179 and a forward implied P/E of 99. Export controls and hyperscaler capex digestion remain live risks. Broadcom (AVGO) Broadcom (NASDAQ:AVGO) is the most aggressive pullback of the three. Shares trade at $372.10 as of June 10, down 22% over the past week from $479.23 and off 13% over the past month. The stock sits 5% below its 52-week high of $495 after the post-earnings reset. The fundamentals behind that selloff are strong. Q2 FY26 revenue was $22.187 billion, up 48% YoY, and non-GAAP EPS of $2.44 marked the eighth consecutive EPS beat. AI semiconductor revenue reached $10.80 billion, up 143% YoY, with free cash flow of $10.262 billion at 46% of revenue. CEO Hock Tan guided forward growth: “In Q3 we expect semiconductor revenue from AI to grow over 200 percent year-over-year to $16.0 billion.” Consolidated Q3 revenue guidance of $29.4 billion implies 84% YoY growth. Analyst targets average $522.06 with 92% bullish sentiment, and Benzinga noted that single-session declines of over 15% have occurred only three times in company history, each preceding strong 6-12 month returns. Risk: The June selloff hinged on the AI guide coming in below the $17.2 billion whisper number, alongside declining gross margin outlook. Post-VMware leverage and hyperscaler concentration amplify any miss. What to Watch Next The June pullback compressed valuations across the three primary AI compute, accelerator, and custom silicon plays without breaking the demand curve. With NVIDIA guiding to $91 billion in Q2 revenue, AMD to 46% YoY growth, and Broadcom to 84% YoY consolidated growth in Q3, the next leg depends on hyperscaler capex commentary and whether export policy on China data center compute shifts before fiscal year ends. |
|||
|
Saved
2026-06-13 15:49
1mo ago
Published
2026-06-13 11:39
1mo ago
|
Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow | FMP Stock News | |
|
Original source text
© ANDREI ASKIRKA / Shutterstock.comAutomatic Data Processing (NASDAQ:ADP | ADP Price Prediction) is a stock worth owning for decades because payroll is non-discretionary, switching costs are punishing, and the company has compounded shareholder capital through every economic regime since the Nixon administration. For a retirement-focused investor who has been burned chasing themes, ADP is the rare name that rewards patience. Pillar 1: Durability That Borders on Infrastructure ADP processes payroll, benefits, and tax compliance for over a million clients worldwide, and once an employer wires its workforce architecture into the platform, changing providers is an operational nightmare that risks severe operational disruption. That stickiness shows up in the numbers: client revenue retention hit a record 92.1% in FY25, and Employer Services revenue grew 7% in Q3 FY26 with segment margin expanding 130 basis points to 41.1%. The business looks less like software and more like plumbing. CEO Maria Black framed the moat plainly: “Organizations around the world trust us as their partner for their most critical workforce functions because we have the data and expertise to address the rapidly changing world of work.” Pillar 2: Income That Compounds Without Drama ADP is a Dividend Aristocrat with over 50 consecutive years of annual dividend increases. The quarterly payout has climbed from $0.07625 in 1999 to $1.70 in 2026, and the company pays a current yield of roughly 2.83%. Management is also shrinking the share count, repurchasing $1.463 billion of stock in the nine months ended March 31, 2026. Then there is the float. ADP holds employer payroll funds in escrow before remitting them, and that pool generated $403.9 million of interest income in Q3 FY26, up 14% year over year, on average client balances of $48.3 billion. Full-year FY26 client fund interest guidance was raised to $1.340 to $1.350 billion. That is high-margin income generated from money that is not even ADP’s. Pillar 3: Built to Survive the Cycle Companies must pay employees in any economy, which is why ADP delivered four consecutive earnings beats and raised FY26 guidance to 10% to 11% adjusted diluted EPS growth even as U.S. pays per control grew just 1%. The stock carries a beta of 0.845 and trades at a forward earnings multiple of 19x, a reasonable price for a business that produced $4.94 billion in operating cash flow in FY25. Over the past decade, ADP shares have returned 220.23% before counting dividends. The One Scenario Where It Lags In a sharp falling-rate environment paired with rising unemployment, float income compresses and pays-per-control slows. ADP has lived through that combination before. The recurring fee base, sticky retention, annual price increases, and buyback machine keep the long-term compounding intact even when the float tailwind goes quiet. The dividend grew through 2008 and 2020 anyway. For long-term holders, the historical pattern has rewarded reinvesting the dividend and tuning out short-term price action. |
|||
|
Saved
2026-06-13 15:47
1mo ago
Published
2026-06-13 10:22
1mo ago
|
A $650,000 Portfolio That Could Send You to the Super Bowl Every Year | FMP Stock News | |
|
Original source text
A Super Bowl weekend is one of the most in-demand and expensive recurring trips in American life. Tickets, airfare, hotels, meals, and ground transportation commonly run $8,000 to $15,000 per couple, so a realistic annual budget lands near $12,000. Can your portfolio can pay for one every February without ever touching principal? That is the work a $650,000 portfolio can do, and the path you choose to get there matters more than the headline yield.The Math Behind the Annual Ticket The underlying math is straightforward: divide the annual income target by the portfolio yield to estimate the capital required. Generating $12,000 per year requires approximately $400,000 at a 3% yield, $300,000 at 4%, $200,000 at 6%, $120,000 at 10%, and $100,000 at 12%. A $650,000 portfolio would comfortably exceed the $12,000 annual income goal across all of those yield levels. The more important question is not whether the target can be reached, but how much excess income you want, how much dividend growth you expect over time, and how much risk to principal and income stability you are willing to accept in pursuit of a higher yield. Conservative Tier: 3% to 4% Dividend Growers This is the dividend-aristocrat lane: large-cap consumer staples, healthcare, and regulated utilities. Yields are modest, but distributions tend to grow faster than inflation. Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) yields about 2.3% after 64 consecutive years of increases, with the latest hike lifting the quarterly payout to $1.34. Procter & Gamble (NYSE:PG) yields around 3% and just delivered its 70th consecutive annual raise, with FY26 plans for roughly $10 billion in dividends and $5 billion in buybacks. At a 3.5% blended yield, $650,000 throws off roughly $22,750 a year. That covers a couple’s Super Bowl trip with almost $10,000 left over for off-season travel, and the income stream itself is engineered to compound. Moderate Tier: 5% to 7% REITs and Utilities For true moderate yield, Realty Income (NYSE:O) pays a monthly $0.2705, yielding about 5.4% after 114 consecutive quarterly increases and 670 straight monthly payments. Regulated utilities in the Southeast offer a similar profile, leaning on data center demand across the Southeast. A $650,000 sleeve at a 6% blended yield generates roughly $39,000 in annual income. The trip is funded three times over. The tradeoff is slower distribution growth and more sensitivity to long Treasury yields, which currently sit near 4.5%. Aggressive Tier: 8% to 14% BDCs and Mortgage REITs Ares Capital (NASDAQ:ARCC) yields roughly 10% on a $0.48 quarterly payout, backed by a portfolio earning 10% on debt investments at amortized cost. A leading mortgage REIT yields about 14% on a $0.12 monthly dividend, but Q1 2026 brought a $0.17 per share net loss and a 6% drop in tangible book value to $8.38. At a 10% blended yield, $650,000 produces $65,000 a year. That funds a Super Bowl trip, a cruise, and a European vacation. AGNC has cut its dividend twice in six years, falling from $0.18 to $0.12 monthly, and its shares still trade near $10. High current yield, real principal risk. The Compounding Insight The cost of the trip will not remain $12,000 forever. Inflation steadily raises the price of airfare, hotels, meals, tickets, and other travel expenses. Even if general inflation moderates, travel-related costs often rise faster than the headline rate. That is why dividend growth can matter more than starting yield. A portfolio yielding 3.5% today that increases its distributions by 6% to 8% annually could potentially double its income within a decade. By contrast, a portfolio yielding 12% that produces little growth, or experiences dividend cuts, may generate more income today but struggle to keep pace with rising costs over time. The goal is not simply to fund this year’s trip. It is to create an income stream that can continue funding future trips without losing purchasing power. Three Moves to Make This Week Price your actual trip. Build a real budget for tickets, flights, and four hotel nights in the host city. Most readers overestimate or underestimate by thousands. Compare 10-year total returns. Run a dividend-growth basket against a high-yield basket over the last decade. The growth side usually wins on total return, even when starting yields look unimpressive. Open a dedicated “experience” account. Route distributions from a specific sleeve into one brokerage account used only for travel. When the cash is there, the trip stops feeling like a splurge. |
|||